FIELD OF THE INVENTION

The present invention belongs to chemical medicine field, and particularly relates to pyrimido[4,5-d]pyrimidineone compounds, or pharmaceutically acceptable salts, stereoisomers or prodrugs thereof; medical compositions containing the compounds; and use of the compounds and compositions in drug preparations.

BACKGROUND OF THE INVENTION

Both in the world and China, the chronic diseases (non-infectious diseases) represented by malignancy tumor (cancer), cardiovascular disease and diabetes, are becoming the major long-term threat to human. On 19 May 2008, the world health organization (WHO) in its latest published report explicitly indicated the non-infectious disease was becoming the most lethal human â€œkillerâ€ . Among of them, cancer is listed the first killer. In 2004, there were 7.4 million people died from cancer in the world, and the situation in china is more terrible. At the end of April in 2008, it was published in the third national death retrospective survey that the china's urban and rural death rate increased by more 80% in the last three decades, and one out of four or five people died from cancer. Every year the total population who die from cancer is closed to 2 million. Recently, the advance in therapeutic approach and drug offers hope to patients. However, there is still an urgent need to solve the bottleneck problems, such as side effects, poor response, recurrence and metastasis of tumor in traditional treatment. The individual therapy and targeted therapy are considered as the hope to break the bottleneck in lung cancer therapy by international medicine.

Tumor molecular targeted therapy is a therapeutic approach which selectively kills tumor cells through chemical or biological method based on key molecules closely related to tumor growth. The targeted therapy is characterized by high specificity, high selectivity and low toxicity. In addition, when it is used in combination with other drugs, it can strengthen effects of traditional chemotherapy and radiotherapy, and reduce recurrence after recovery. The targeted drugs represented by imatinib (STI571, Novartis, 2001), gefitinib (ZD1839, AstraZeneca, 2003), erlotinib (OS1774, Genentech and OSIP, 2004), sorafenib (Bay 43-9006, Bayer and Onyx, 2005), sunitinib (SU11248, Pfizer, 2006) and dasatinib (BMS-354825, Bristol-Myers Squibb, 2006) opened new age for tumor chemotherapy. Tumor targeted therapy developed rapidly in just a few years, and it had an impact on traditional concept and model of drug delivery. For example, since the targeted drug has low side effect, its dose in clinical I trails always does not reach to the maximum tolerated dose or leads to dosing-limiting toxicity. It is not need to use the maximum tolerated dose to reach the satisfactory effect. Therefore, the tumor targeted therapy is a hot topic and developing trend in tumor therapy.

Protein tyrosine kinases (PTKs) are protein enzymes capable of catalyzing the phosphorylation of phenolic hydroxyl group in tyrosine residues of various key proteins, resulting in activation of protein function. There are about 520 protein kinases in human, half of them are tyrosine kinases. They play an important role in cellular signal transductional pathway, and regulate a series of physiological process, such as cellular growth, differentiation and apoptosis. And dysfunction of protein tyrosine kinases can cause a series of diseases in human body. For instance, their overexpression would disturb the normal cell growth regulation, resulting in tumor. In addition, the abnomal expression of protein tyrosine kinases has been closely associated with tumor invasion, metastasis, angiogenesis and chemotherapy resistance. Therefore, the research of antitumor drug targeting tyrosine kinases has become an international hotspot, and attracts investment from national drug discovery organizations.

Epidermal growth factor receptor (EGFR) is a member of receptor tyrosine kinases, which regulates cell proliferation, survival, adhesion, metastasis and differentiation. Overexpression or constitutive activation of EGFR has been observed in many cancers, such as lung cancer, breast cancer and prostate cancer. EGFR is a kind of transmembrane protein and its family has four members: EGFR, HER-2, HER-3 and HER-4. The abnormal activation of EGFR and HER-2 plays a key role in tumor differentiation and growth, and blocking their activation has been validated in clinical tests as major targeted treatment for tumor cells. Taking lung cancer as an example, EGFR is expressed in 50% of NSCLC patients and is associated with poor prognosis. The two factors allow EGFR and its family members to be major candidate of targeted therapy. Two small molecules targeting EGFR, gefitinib and erlotinib, were rapidly approved for treatment of advanced NSCLC patients, who have not response to traditional chemotherapy.

Early clinical date indicated that 10% of NSCLC patients have response to getifinib and erlotinib. This significant clinical effect has been observed in special patients, including East Asian female non-smokers and carcinoma patients showing bronchioloalveolar pathology. Molecular evaluation showed that in most cases, the patients who have response to the drugs harbor special mutants in EGFR encoding gene. Of note are two particular mutations: deletion of amino acids 747-750 in exon 19 (del(746-750)) and leucine to arginine substitution at 858 in exon 21 (L858R) which together account for approximately 66% of all alterations. The activating mutations in EGFR kinase domain highly activate kinases, inducing an â€œaddictionâ€ of tumor to EGFR survival signal. Calculated prospective clinical studies demonstrated that the patients harboring activating mutations in EGFR have higher response rate than the NSCLC patients with wild type EGFR, and their PFS and OS significantly prolong. But even so, the PFS of most patients with activating mutations is not more than 12-14 months, in other word, these patients suffer from drug resistance to TKI. And the mechanism of acquired drug resistance and its clinical coping strategies have become another research hotspot.

The drug resistance mechanisms of targeting EGFR inhibitor can be classified into two categories: resistance mutations and alternative signaling pathway. Drug resistance mechanism 1: A secondary EGFR mutation, T790M, is a point mutant in exon 20, and is thought to one of recognized drug resistance mechanisms. The exact resistance mechanism remains to be determined. It was first predicted that the T790M mutation sterically hindered the binding of TKIs to the EGFR kinase domain, by the introduction of a bulky Met residue, thus resulting in drug resistance. A recent report, however, directly showed that L858R/T790M mutant binds ATP more tightly than the L858R mutant and TKIs are ATP-competitive inhibitors, thus causing the binding affinity between TKIs and kinase domain decreased. Another one of controversial issue about T790M is whether this mutant is primary or acquired after treatment of TKIs. The T790M was first found in NSCLC patients who failed to response to TKIs, but then, it was identified in samples that did not receive any treatment. Therefore, it is now thought that this mutation also exists in tumor tissue that does not receive treatment of TKIs, but only in few cell clones, which were identified after treatment due to their resistance to TKIs. There are several drug resistance mutations that have similarities to T790M, such as D761Y, L747S, T854A, etc. These mutations are called â€œnon-T790M acquired mutationsâ€ , which account for less 5% of the total. Drug resistance mechanism 2: Amplification of MET is another EGFR-TKI acquired resistance that was identified in 2007. MET is a kind of transmembrane tyrosine kinase receptor. There is about 20% wild type MET gene amplification in EGFR mutant positive NSCLC patients who were resistance to TKIs, and most of whom did not harbor MET amplification before treatment. MET, together with ErbB family members, bypasses EGFR downstream signaling pathway mediated by AKT to boost tumor cell growth and inhibit cell apoptosis. In vivo trials, inhibiting MET signaling pathway through siRNA technology can recovery the sensitivity of drug-resistant patients to gefitinib. Combined inhibition of EGFR and MET is able to overcome TKI drug resistance induced by MET amplification. There are still several receptors that have similar effects to MET. A recent in vivo TKI resistance model showed that IGF-1R also can bypass EGFR to activate its downstream signaling pathway. However, for technique hindrance, it is difficult to detect activating IGF-1R in patients' samples. These drug resistance mechanisms through bypassing EGFR and its downstream signaling pathway are called â€œalternative signaling pathwayâ€ . The drug resistance mechanism of about 30-40% of the EGFR mutation positive and TKI resistant patients who have neither primary mutation nor MET amplification remains to be discovered.

There are three clinical strategies for drug resistance. Strategy 1 is to continue adopting the cross-use of EGFR TKI, gefitinb and erlotinib. Despite of certain effect, the effect of continue use of TM is limited. Strategy 2 is to discovery novel EGFR-TKI. Clinical study showed that EGFR irreversible inhibitors can in vivo inhibit T790M. Then, many EGFR irreversible inhibitors were discovered, called â€œsecond-generation EGFR TKIâ€ . To date, some of irreversible inhibitors have progressed into clinic from pre-clinic, such as neratinib, XL647, BIBW2992 and PF-00299804. Neratinib is a pan ErbB (EGFR, ErbB and ErbB3) irreversible inhibitor, which are under clinical trials. Based on clinical I study, it was studied to reveal whether neratinib (240 mg/d) can overcome T790M mutation or MET amplification-medicated TM resistance in NSCLC patients after treatment of gefitinib or erlotinib. However, adverse results were showed in some clinical studies. For example, a PC-9 cell line with deletion of EGFR 19 exon developed drug resistance when treated with neratinib; In cell harboring L858R/T790M xenograft mouse model, single treatment of neratinib did not mitigate tumor growth. Therefore, the effect of neratinib on T790M patients remains to be determined. XL647 can irreversibly inhibit EGFR, HER2, VEGFR-2 and EphB4 and suppress the tumor growth in cell harboring L858R/T790M xenograft mouse model. In 2008, a clinical II study of XL647 demonstrated that there was only one patient achieving remission after treatment of XL647 (300 mg/d) in 34 NSCLC patients, who progressed again or harbored T790M mutation after tumor's remission for more than 3 months when treated with gefitinib or erlotinib. This patient was non-smoker, had deletion of 19 exon in EGFR and there is not T790M mutation in the blood of this patient, but no one with T790M mutation received remission and most patients progressed in 2 months. BIBW2992 is a dual EGFR and ErbB2 irreversible inhibitor. Clinical II study showed that BIBW2992 can mitigate tumor in patients with deletion of 19 exon, L858R, L861Q, or G719S/S768I. BIBW2992 is used to treat the patients who have received remission after treatment of gefitinib or erlotinib and failed to response to third-in-class chemotherapy, which is under clinical III study, and a study is conducted in randomized clinical IIb/III trials on BIBW2992 compared with placebo in these patients. These studies would help researchers to determine whether BIBW2992 is good for gefitinib or erlotinib resistant patients. PF-00299804 is a pan ErbB inhibitor, and a patient with T790M mutation received remission treated with it in a clinical I trial. A clinical II study is being conducted, in which PF-00299804 (45 mg/d) is used to treat the NSCLC patients with wild type KRAS who failed to chemotherapy or erlotinib. Strategy 3 is therapy for other targets. Since â€œalternative signaling pathwayâ€ plays a vital role in EGFR-TKI resistance, targeted drugs for these pathways are constantly emerging. MET-TKI probably plays a role in patient with MET amplification. Clinical study showed that the combination of EGFR-TKI and MET-TKI had effects on the cell line with both EGFR mutation and MET amplification, but single use was efficacious. Most important, there are about half of patients harboring both MET amplification and EGFR T790M mutation, then, MET-TKI probably need to be used in combination with T790M inhibitors. XL84 is a novel TM, which has inhibition on MET, VEGFR-2 and RET. Other MET inhibitors, such as ARQ197, PF-2341066 and SGX523 are under development. PF-2341066 is a selective c-MET and ALK TM, which showed good effects on tumor growth, especially in the patients with ALK-EML4 fusion gene, in clinical I trials. And PF-2341066 is being under clinical II/III trials, which has become a new hotspot in targeted therapy area. Some drugs targeting other alternative signaling pathways, such as IGFR-1R inhibitors and HSP90 inhibitors, are also on the way.

In a word, current EGFR-TKIs do not still relieve clinical stress caused by drug resistance. In addition, most existing drugs are EGFR reversible or irreversible inhibitors based on 4-anilinoquinazolines scaffold, which display poor selectivity over wild type cell, resulting in side effects. Therefore, there is an urgent need to discovery novel structural compounds to overcome resistance and improve selectivity.

SUMMARY OF THE INVENTION

In one aspect, the present invention provides a novel pyrimido[4,5-d]pyrimidinyl compound of formula (I) or (II):

[Image Omitted]

- or a pharmaceutically acceptable salts, isomers or prodrugs thereof,
  wherein, Y is â€”CH or N;
  R₁is selected from:

1) H;

2) C₁-C₅alkyl;
3) C₃-C₆cycloalkyl;
4) C₁-C₅fluoroalkyl;
5) (CH₂)_nX, n is an integer of 0-6, X is OH, NH₂, C₁-C₆heteroalkyl, or C₃-C₇heterocycloalkyl;
6)

[Image Omitted]

A₁, A₂, A₃, A₄, A₅are each independently selected from:
a. H;
b. halo;
c. â€”CN;
d. â€”NO₂;
e. â€”OH;
f. â€”NH₂;
g. C₁-C₆alkyl;
h. C₃-C₆cycloalkyl;
i. C₁-C₆fluoroalkyl;
j. C₁-C₆heteroalkyl;
k. C₁-C₇heterocycloalkyl;
l. the esters, amide, sulfone, sulfoxide, urea formed from the alkyl above;
wherein, the heteroatom contained in the above heteroalkyl or heterocycloalkyl is O, N or S;
R₂is selected from:

1) H;

2) C₁-C₅alkyl;
3) C₃-C₆cycloalkyl;
4) C₁-C₅fluoroalkyl;
5) aryl;
6) heterocycloalkyl;
wherein, the heteroatom contained in the above heterocycloalkyl is O, N or S;
R₃is selected from:

1) H;

2) halo;

3) NH₂, OH, CN, NO₂;

4) C₁-C₅alkyl;
5) C₃-C₆cycloalkyl;
6) aryl;
7)

[Image Omitted]

wherein W is: a. CH₂; b. CH₂CH₂; c. 0; d. S; e. NH; f. NR; R is C₁-C₅alkyl or aryl;
R₄is selected from:

1) H;

2) halo;
3) C₁-C₅alkyl;
4) C₃-C₆cycloalkyl;
5) aryl;
wherein, the alkyl, aryl described above are each independently substituted by 0, 1, 2 or 3 substituents selected from R₅;
R₅is selected from:

1) H;

2) halo;
3) C₁-C₃alkyl;
4) C₃-C₆cycloalkyl;
5) C₁-C₃alkoxy;
6) C₁-C₃fluoroalkyl;
7) heterocycloalkyl;
8) C₀-C₃alkylene heterocyclic;
9) phenyl;
wherein, the heteroatom contained in the above heterocycloalkyl or alkylene heterocyclic is O, N or S.

In another aspect, the present invention further provides a compound having the structure of formula (III):

[Image Omitted]

- or the pharmaceutically acceptable salts, isomers or prodrugs thereof,
  wherein R₃is selected as above;
  R₁is selected from:

1) H;

2) methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, n-pentyl, isopentyl, neopentyl;
3) cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl;
4) (CH₂)_nX, n is an integer of 0-6, X is â€”OH, â€”NH₂, â€”OCH₃, â€”OCH₂CH₃, â€”OCH₂CH₃OCH₃, â€”OCH₂CH₃OCH₂CH₃, â€”SCH₃, â€”N(CH₃)₂, N-methylpiperazinyl, morpholinyl, thiomorpholinyl, piperidinyl, pyrrolidinyl, 4-N,N-dimethylpiperidinyl, 1-methyl-4-(piperidin-4-yl)piperazinyl, imidazole, 6-(4-methylpiperazine-1-yl)-3-pyridinyl;
5)

[Image Omitted]

A₁, A₂, A₃, A₄, A₅are each independently selected from:
a. H;
b. F, Cl, Br, I;
c. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, n-pentyl, isopentyl, neopentyl;
d. â€”OCH₃, â€”OCH₂CH₃, â€”OCH(CH₃)₂, â€”OC(CH₃)₃, â€”OCH₂CH₃OCH₃, â€”OCH₂CH₃OCH₂CH₃;
e. â€”CF₃;
f. N,N-dimethylaminoethoxyl, N,N-dimethylaminopropoxyl, 2-(N-methylpiperazine)ethoxyl, 2-(N-acetylpiperazine)ethoxyl, 2-morpholinylethoxyl, 2-thiomorpholinylethoxyl, 2-pyridinylethoxyl, 2-pyrrolidinylethoxyl, N-methylpiperazinyl, morpholinyl, thiomorpholinyl, piperidinyl, pyrrolidinyl, imidazole, 3-N,N-dimethylpyrrolidinyl, 4-N,N-dimethylpyridinyl, 4-acetylpiperazinyl, 1-methyl-4-(piperazine-4-yl)pyridinyl, 4-(4-methylpiperazine-1-yl)methyl, (1-methylpiperidine-4-yl)amino, piperazine-2-one-4-yl, 1-methylpiperazine-2-one-4-yl;
g. the esters, amide, sulfone, sulfoxide, urea formed from the groups above;
R₂is selected from:

1) H;

2) methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, n-pentyl, isopentyl, neopentyl;
3) cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl;
4) phenyl, 4-methoxylphenyl, biphenyl, 4-phenoxylphenyl, 4-benzyloxylphenyl, 2,4-dichlorophenyl, 3-chloro-4-fluorophenyl, single or multiple substituted phenyl, benzyl, substituted benzyl, 1-naphthyl, 2-naphthyl, pyridinyl;

The 2,4,5,6-position of aromatic ring containing M is mono or multi-substituted by M, wherein

M is selected from:

1) H;

2) halo;

3) â€”CN;4) â€”NO₂;5) â€”OH;6) â€”NH₂;

7) C₁-C₆alkyl;
8) C₃-C₆cycloalkyl;
9) C₁-C₆fluoroalkyl;
10) C₁-C₆heteroalkyl;
11) C₁-C₇heterocycloalkyl;
12) the esters, amide, sulfone, sulfoxide, urea formed from the groups above;
wherein, the heteroatom contained in the above heteroalkyl or heterocycloalkyl is O, N or S.

In another aspect, the present invention further provides a compound having the structure of formula (IV):

[Image Omitted]

- or the pharmaceutically acceptable salts, isomers or prodrugs thereof,
  wherein R₃, R₂, M are selected as above;
  R₆, R₇are each independently selected from:

1) H;

2) methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, n-pentyl, isopentyl, neopentyl;
3) cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl;
4) phenyl;
5)

[Image Omitted]

W is selected from: â€”CH₂, â€”CH₂CH₂, O, S, â€”NH, â€”NR; R is methyl, ethyl, or phenyl;
R₄is selected from:

1) H;2) F, Cl, Br, I;

3) methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl;
4) cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl;
5) phenyl, mono- or multi-substituted phenyl.

Another objective of the present invention is to provide a pharmaceutical composition that is useful for treating cancer.

According to one embodiment of the present invention, a technical solution for achieving the above mentioned objective is as followings:

A pharmaceutical composition comprises of the above mentioned compound, i.e. 7-(substituted amino)-3,4-dihydropyrimido[4,5-d]pyrimidin-(1H)-one or the pharmaceutically acceptable salts, prodrugs or stereoisomers thereof.

It is a further objective for the present invention to provide use of the above-mentioned compound.

According to one embodiment of the present invention, a technical solution for achieving the above objective is as followings:

Use of the compound mentioned above or the pharmaceutically acceptable salts, stereoisomers or pro-drugs thereof in the preparation of drugs for treating cancer.

Preferably, the mentioned cancer is any one of non-small cell lung cancer, small cell lung cancer, lung adenocarcinoma, squamous cell lung carcinoma, pancreatic cancer, breast cancer, prostate cancer, liver cancer, skin cancer, squamous cell carcinoma, nasopharyngeal carcinoma, leukemia, histiocytic lymphoma and nasopharyngeal carcinoma.

The 2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidinyl compounds which have the general formula (I) or (II) could inhibit multiple cancer cells proliferation. They specially inhibit the proliferation of non-small-cell lung cancer (NSCLC) H1975 which bears EGER^L58R/T790Mor EGFR^E745^â€”^A750/T790M. Compared to the cancer cell bearing the wild type EGFR, these compounds can work 10, 100 or 1000 times more effective on mutated cancer cells. This kind of compound is a new series inhibitors that can overcome the gefitinib-resistant nonsmall cell lung cancer.

The above mentioned compounds 7-(substituted amino)-3,4-dihydropyrimido[4,5-d]pyrimidin-(1H)-ones and their pharmaceutically acceptable salts or prodrugs can effectively inhibit multiple cancer cells proliferation. They can still inhibit the phosphorylation of EGFR and other members of Her family. These compounds can be used as anticancer drugs, and they can overcome the gefitinib-resistant. As can be understood by the technical person in the filed, the compounds and their pharmaceutically acceptable salts of the present invention can be used for the therapeutic application of over proliferative diseases including human cancers or mammalian cancers.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1-11 illustrate the efficacies using vitro kinase assays with WT EGFR.

FIGS. 12-22 illustrate the efficacies using vitro kinase assays with EGFR T790.

FIGS. 23-26 illustrate the efficacies agaist lung cancer cells using MTT.

FIGS. 27 and 28 illustrate the effect of compound C-EGF06 on the lung cancer cell cycle.

FIG. 29 illustrates the effect of compound C-EGF06 on the lung cancer cell apoptosis.

FIG. 30. illustrates the effect of compound C-EGF06 on the lung cancer cell signaling pathway.

DETAILED DESCRIPTION OF THE INVENTION

In the compounds according to the present invention, when any variables (such as R1, R, etc.) appear more than once in any component, the definitions every time they occur are independent from the definitions they appear other times. Also, allow substituent and variable combination, as long as the combination makes stable compounds. The line crossing from the substituent to sing system means the bond indicated can link to any atom of the ring which can be substituted. If the ring system is multiple ring system, it means the bond only connects to any appropriate carbon atom of the adjacent ring. To understand the person with common techniques in the art can choose the compounds substituent and replacement type in order to provide the synthetic compounds that are chemically stable and can be synthesized from easily available materials by the techniques in the field and the methods mentioned below. If the substituent itself is replaced by more than one group, these groups can be in the same carbon atom or different carbon atoms, as long as the structure is stable. The phrase â€œoptionally substituted by one or more substituentsâ€ is equivalent to the phrase â€œoptionally substituted by at least one substituentâ€ , and in a preferable embodiment, there will be 0-3 substituents.

In this invention, the term â€œalkylâ€ and â€œsub-alkylâ€ means a branched-chain or straight chain alkyl group with the certain number of carbon atoms. For example, the definition of â€œC₁-C₅â€ in â€œC₁-C₅alkylâ€ means straight-chain or branched-chain alkyl group with 1, 2, 3, 4 or 5 carbon atoms. For example, â€œC₁-C₅alkylâ€ includes methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, isobutyl, pentyl, etc. The term â€œcycloalkylâ€ refers to a specific single saturated ring alkyl with the certain number of carbon atoms. For examples, â€œcycloalkylâ€ includes cyclopropyl-, methyl-cyclopropyl-, 2,2-dimethyl-cyclobutyl, 2-ethyl-cyclopentyl-, cyclohexyl etc.

In this invention, the term of â€œhetero arylâ€ is a stable monocyclic ring with up to six atoms or a stable bicyclic ring in which each ring contains up to six atoms. At least one of the rings is an aromatic ring containing 1-4 atoms selected from O, N or S. Hetero aryl groups include but not limit to: imidazolyl, triazolyl, pyrazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, pyrazinyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl. About the definition of hetero aryl, any hetero aryl N-oxidation derivatives containing N atom should also be added. When hetero aryl substitutent group is a bicyclic ring and one of the two rings is non-aromatic or non-heteroatom-containing ring, the bicyclic ring is connected via the aromatic ring or the heteroatom-containing ring.

The term of â€œheterocycleâ€ or â€œheterocyclicâ€ refers to an aromatic or nonaromatic ring containing 5-6 atoms, in which contains 1-4 hetero atoms such as O, N, S. â€œHeterocycleâ€ includes hetero aromatic ring as mentioned above; it also includes dihydro and tetrahydro analogs. â€œHeterocyclesâ€ further include but not limit to: imidazolyl, indolyl, isothiazolyl, isoxazolyl, oxadiazolyl, oxazolyl, oxetanyl, pyranyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, quinazolinyl, tetrazolyl, thiadiazolyl, thiazolyl, thienyl, triazolyl, 1,4-alkyl-dioxinyl, alkyl pyrrolidinyl, dihydro-imidazolyl, dihydro-isoxazolyl, dihydro-iso thiazolyl, dihydro-oxadiazolyl, dihydro-oxazolyl, dihydro-pyrazinyl, dihydro-pyrazolyl, dihydro-pyridyl, dihydro-pyrimidinyl, dihydro-pyrrolyl, dihydro-tetrazolyl, dihydro-thiadiazolyl, dihydro-thiazolyl, dihydro-thienyl, dihydro-triazolyl, methylene dioxy-benzophenone acyl, tetrahydrofuranyl, tetrahydrothiopheneyl, and their N-oxides etc. The linkage of heterocycle substituent can be achieved through C atom or heteroatom. In one embodiment, heterocycle is selected from imidazolyl, pyridyl, 1-pyrrolidone, 2-piperidone, 2-pyrimidone, 2-pyrrolidone, thienyl, oxazolyl, triazolyl, isoxazolyl, etc.

As understood by the person skilled in the prior art, â€œhaloâ€ or â€œhalogenâ€ in the present specification means chlorine, fluorine, bromine and iodine.

Unless specially mentioned, alkyl, cycloalkyl, aryl, hetero aryl, heterocyclic groups can be substituted or not be substituted. For example, C₁-C₆alkyl group can be substituted by one, two, or three substitutents selected from OH, halogens, alkoxyl, dialkylamino, or heterocyclic ring such as morpholinyl, piperidinyl groups.

In an embodiment, â€œHetâ€ is defined as being able to cooperate with N atom which connects the Het to form a 4-7 membered mono-ring or a bicyclic heterocylic ring in which each ring is a 4-7 membered ring, wherein the mono-ring or bicyclic heterocylic ring may further comprises 1-2 hetero atoms selected from N, O, S, and said heterocycle can also be optionally substituted by one or more substituents selected from R₂. The hetero cyclic rings formed include but not limit to the following heterocycles, and it shall be remembered said heterocycle selectively substituted by one or more (preferably one, two or three) substituents selected from R₂

[Image Omitted]

The present invention relates to the free form of compounds with formula (I)-(II), and it also relates to their pharmaceutically acceptable salts or stereoisomers. The specific examples in the invention are the protonated salts of amines. The term â€œfree formâ€ means that the amines are not in the form of salts. The included pharmaceutically acceptable salts include not only the exemplary salts of the specific compounds of the present disclosure, but also the typical pharmaceutically acceptable salts of all the compounds of formulas I-IV in free form. The specific compounds in free form can be separated by means of known technology in the art. For example, appropriate dilute aqueous solutions of alkali, such as dilute aqueous solution of NaOH, dilute aqueous solution of K₂CO₃, dilute ammonia, dilute aqueous solution of NaHCO₃, etc., can be used for treating the salts to make the free form regenerate. A compound in free form has some different properties with such compound in its salt form, for example, their respective solubilities in a polar solvent are different; however, the acid salts and basic salts according to the present invention are equivalent to their respective free form in other pharmaceutical aspects.

The pharmaceutically acceptable salts according to the present invention can be synthesized from the compound of the present invention containing a basic portion or an acidic portion by conventional chemical methods. Usually, a salt of a basic compound is prepared by ion exchange chromatography or by reacting a free-form base with stoichiometric amount or excessive amount of an inorganic or organic acid according to the required salt form in an appropriate solvent or combination of a variety of solvents. Similarly, a salt of an acidic compound is prepared by reacting the compound with an appropriate inorganic or organic base.

Therefore, â€œpharmaceutically acceptable saltsâ€ in the invention mean the normal nontoxic salts formed by the basic compounds in the invention with organic acids and inorganic acids. For example, the normal nontoxic salts are prepared from inorganic acids that include hydrochloric acid, hydrobromic acid, sulfuric acid, sulfamic acid, phosphoric acid, nitric acid, and from organic acids that include acetic acid, propionic acid, succinic acid, glycolic acid, stearic acid, lactic acid, malic acid, tartaric acid, lemon acid, ascorbic acid, bashing acid, maleic acid, hydroxy-maleic acid, phenylacetic acid, glutamic acid, benzoic acid, salicylic acid, sulfanilic acid, 2-acetoxy-benzoic acid, p-toluenesulfonic acid, methanesulfonic acid, ethane disulfonic, oxalic acid, hydroxyethyl sulfonic acid, trifluoroacetic acid etc.

When the compound of the present invention is acidic, then the appropriate â€œpharmaceutically acceptable saltsâ€ refer to salts prepared from pharmaceutically acceptable nontoxic bases including inorganic and organic bases. The salts prepared from inorganic bases includes aluminum salts, ammonium salts, calcium salts, copper salts, ferric salts, ferrous salts, lithium salts, magnesium salts, manganic salts, manganous salts, potassium salts, sodium salts, zinc salts, etc. Particulary, ammonium salts, calcium salts, magnesium salts, potassium salts and sodium salts are preferable. The salts prepared from organic nontoxic bases includes salts of primary amines, secondary amines and tertiary amines, wherein the amines can be substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins such as arginine, betaine, caffeine, choline, N,Nâ€²-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, aminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydroxocobalamin, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, etc.

Berg et al described the preparation of pharmaceutically acceptable salts as above mentioned or other typical pharmaceutically acceptable salts in Pharmaceutical Salts, J. Pharm. Sci. 1977, 66: 1-19 in more details.

Since under physiological conditions, a deprotonated acidic moiety of a compound, e.g. a carboxyl, may be of anion with charge which can be balanced/offset by a protonated or alkylated basic moiety with cation contained therein, for example, a tetravalent nitrogen atom, therefore, it should be noted that compounds of the present invention are potentially internal salts or zwitter.

In addition to the known in the literature or exemplified in the experimental procedures in the standard methods, the compounds mentioned in this invention can be prepared in the same way with the following program. Therefore, the following program is just used for illustrative. It is not limited to the listed compounds or any particular substituent. The number of substituents showed in this program is not required to match the number that used in the claim, and for the purpose of clarity, mono substituent is shown to be connected to the compound of formula (I) or (II) which is capable of having multi substituents as defined above.

Program

The compounds I-IV mentioned in the invention could be synthesized in nine steps by using ethyl 4-chloro-2-(methylthio)pyrimidine-5-carboxylate as the starting material.

[Image Omitted]

In one embodiment, this present invention provides a method of using compounds in formula (I) and their pharmaceutically acceptable salts for treatment of over proliferative diseases including human cancers or mammalian cancers.

In one embodiment, the invention also relates to the compounds designed in the present invention and their pharmaceutically acceptable salts which are used for the treatment or the prevention of over proliferative diseases, such as gastrointestinal stromal tumors (GIST), histiocytic lymphoma, non-small cell lung cancer, small cell lung cancer, lung adenocarcinoma, squamous cell lung carcinoma, pancreatic cancer, breast cancer, prostate cancer, liver cancer, skin cancer, squamous cell carcinoma, nasopharyngeal carcinoma, leukemia, histiocytic lymphoma and nasopharyngeal carcinoma, and so on.

Metabolites-Prodrugs

The metabolites of the compounds and their pharmaceutical salts in the present invention, and prodrugs that are converted to the compounds and their pharmaceutical salts in the present invention are comprised in the claims of the present application.

Combination Therapy

Compounds of Formula I-IV may be used in combination with other drugs that are known to be useful in the treatment or amelioration of the diseases or similar diseases. In the combination administration, such other drugs may be administered, by a route administration and in an amount commonly used, and contemporaneously or sequentially with a compound of Formula I-IV. When a compound of Formula I-IV is used contemporaneously with one or more other drugs, a pharmaceutical composition containing one or more other known drugs and the compound of Formula I-IV is preferred. The combination therapy also comprises therapies in which the compound of Formula I-IV and one or more other known drugs are administered on overlapping schedules. When used in combination with one or more otherdrugs, the compound of Formua I-IV and the other known drugs may be used in lower dosage than when they are used alone.

Drugs or active ingredients used in combination with compounds of Formula I-IV comprises but are not limited to:

- estrogen receptor modulator, androgen receptor modulator, retinoid receptor modulator, cell toxin/cell inhibitor, antiproliferative agents, protein transferase inhibitors, HMG-CoA reductase inhibitors, HIV protein kinase inhibitors, reverse transcriptase inhibitors, angiogenesis inhibitors, cell proliferation and survival signaling inhibitors, interference with the cell cycle checkpoint drugs and apoptosis inducing agent, cytotoxic drugs, protein tyrosine inhibitor, EGFR, VEGFR inhibitors, inhibitors of serine/threonine protein inhibitors, inhibitors of Bcr-Abl, c-Kit inhibitor, Met inhibitors, inhibitors of Raf, MEK inhibitor, MMP inhibitors, inhibitors of topoisomerase, histidine deacetylase inhibitors, proteasome inhibitors, inhibitors of CDK, Bcl-2 family protein inhibitor, MDM2 family protein inhibitors, inhibitors of IAP family proteins, inhibitor of STAT family proteins, PI3K, AKT inhibitors, inhibitors of integrin blockade, IFN-Î±, interleukin-12, COX-2 inhibitor, p53, p53 activator inhibitor, VEGF antibody, EGF antibody, etc.

In one embodiment, drugs or active ingredients used in combination with compounds of Formula I-IV comprises but are not limited to: Aldesleukin, Alendronate, interferon, Alitretinoin, allopurinol, allopurinol sodium, palonosetron hydrochloride, Hemel, amino glutethimide, amifostine, amrubicin, Ann acridine, anastrozole, dolasetron, Aranesp, arglabin, arsenic trioxide, Aromasin, 5-N cytidine, azathioprine, BCG or BCG, Bestatin hydrochloride, betamethasone acetate, betamethasone sodium phosphate, Bexarotene, bleomycin sulfate, broxuridine, bortezomib, busulfan, calcitonin, Alemtuzumab Campath, capecitabine, carboplatin, Casodex, cefesone, Seamus IL, DNR, chlorambucil, cisplatin, cladribine, cladribine, chloride phosphoric acid, Cytarabine, cyclophosphamide, Dacarbazine, Actinomycin D, DNX, dexamethasone, dexamethasone phosphate, estradiol valerate, cefdinir interleukin 2, Methylprednisolone acetate, deslorelin, dexrazoxane, diethylstilbestrol, Diflucan, docetaxel, doxorubicin, doxifluridine, dronabinol, chin-166-chitosan complexes, eligard, rasburicase, epirubicin hydrochloride, aprepitant, epirubicin, alfa-epoetin, erythropoietin, Eptaplatin, levamisole, estradiol formulation, 17-Î²-estradiol, estramustine phosphate sodium, ethinylestradiol, Amifostine, hydroxylphosphate, Etopophos, etoposide, Fadrozole, tamoxifen, filgrastim, finasteride, floxuridine, fluconazole, fludarabine, 5-fluorine BrdU a phosphate, 5-fluorouracil, fluoxymesterone, flutamide, formestane, Cytarabine hydrochloride, Fotemustine, fulvestrant, immunoglobulin, gemcitabine, gemtuzumab ozogamicin, imatinib mesylate, carmustine capsules, goserelin, hydrocortisone, erythro-hydroxy nonyl adenine, hydroxyurea, Ibritumomab Tiuxetan. Idarubicin, ifosfamide, interferon Î±, IFN-Î±2, interferon Î±-2A, interferon Î±-2B, interferon Î±-nl, IFN Î±-n3, interferon Î², interferon Î³-la, IL-2, intron A, Iressa, Irinotecan, Kytril, mushroom polysaccharide sulfate, letrozole, leucovorin, leuprolide, leuprorelin acetate, Levamisole, levorotation folinic acid calcium salt, levothyroxine sodium, levothyroxine sodium, lomustine, lonidamine, dronabinol, nitrogen mustard, Mecobalamin, medroxyprogesterone acetate, megestrol acetate, melphalan, esterified estrogens, 6-Mercaptopurine, mesna, methotrexate, aminolevulinic acid methyl ester, miltefosine, minocycline, mitomycin C, mitotane, mitoxantrone anthraquinone, Trilostane, citric acid adriamycin liposome, Nedaplatin, Pegfilgrastim, oprelvekin, neupogen, nilutamide, tamoxifen, NSC-631570, recombinant human interleukin 1-Î², octreotide, Ondansetron hydrochloride, hydroprednisone oral solution, oxaliplatin, paclitaxel, prednisone, L-asparaginase enzyme sodium phosphate preparation, Pegasys, pentostatin, Picibanil, pilocarpine hydrochloride, adjoin THP, mithramycin, porfimer sodium, prednimustine, Prednisolone Steaglate, prednisolone, Premarin, C kappa umbilical, recombinant human erythropoietin, raltitrexed, Libby, etidronate rhenium-186, rituximab, Redoxon-A, Romo peptide, pilocarpine hydrochloride tablets, octreotide, Sargramostim, semustine, Schizophyllan, sobuzoxane, Methylprednisolone, Paphos acid, stem cell therapy, streptozocin, strontium chloride-89, levothyroxine sodium, tamoxifen, tamsulosin, TNF-alfa, tastolactone, docetaxel, teceleukin, temozolomide, teniposide, propionic acid testosterone, testosterone propionate, thioguanine, thiotepa, thyroid stimulating hormone, Tiludronic acid, topotecan, toremifene, tositumomab, trastuzumab, Treosulfan, Victoria A acid, methotrexate tablets, three methyl melamine, trimetrexate, triptorelin, double hydroxy acetic acidNaphthalene of triptorelin, UFT, uridine, valrubicin, vesnarinone, alkali, vincristine, Vindesine Vinorelbine, virulizin, dextral razoxane, Zinostatin ester, ondansetron, paclitaxel, acolbifene, Interferon r-lb, affinitak, aminopterin, Arzoxifene, Asoprisnil, atamestane, atrasentan, BAY 43-9006, Avastin, CCI-779, CDC-501, Celebrex, cetuximab, crisnatol, cyproterone acetate, decitabine, DN-101, Doxorubicin-MTC, dSLIM, dutasteride, edotecarin, eflornithine, Exatecan, Fenretinide, histamine hydrochloride, holmium-166 DOTMP, ibandronate, IFN-Î³, intron-PEG, ixabepilone, intron keyhole shaped hemocyanin, L-651582, Lanreotide, lasofoxifene, Libra, lonafamib, Miproxifene, MS-209, liposome MTP-PE, MX-6, Nafarelin, Nemorubicin, Neovastat, Nolatrexed, Aolimosen, onco-TCS, osidem, paclitaxel poly glutamic acid ester, pamidronate disodium injection, PN-401, QS-21, R-1549, raloxifene, ranpirnase, 13-cis-Victoria A acid, satraplatin, seocalcitol, T-138067, Tarceva, DHA-PTX, thymosin al, Pirazofurin, tipifarnib, tirapazamine, TLK-286, toremifene, trans MID-lo7R, valspodar, vapreotide, vatalanib, verteporfin, Vinflunine, Z-100 and Zoledronic acid or their combination.

Further explanations are made as following, but those embodiments can not be used to limit the protection scope of the invention.

Example 1N-(3-(3-methyl-7-(methylamino)-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1 (2H)-yl)phenyl)acrylamide (C-EGF21)

[Image Omitted]

Step 1. ethyl 4-(3-(tert-butoxycarbonylamino)phenylamino)-2-(methylthio)pyrimidine-5-carboxylate (2)

[Image Omitted]

Compound 1 (23.3 g, 100 mmol), N-Boc m-Phenylenediamine (20.8 g, 100 mmol), Potassium carbonate (27.6 g, 200 mmol) were solved in DMF (300 mL). The reaction was heated to 80Â° C. under nitrogen and stirred overnight. After being cooled to room temperature, the reaction mixture was added to ice water (1000 mL). Large amount of solid precipitated. The solid precipitate was filtered under reduced pressure, and vacuum dried to give the white solid (38.8 g, 96% yield) as a white solid.

¹H NMR (400 Hz, CDCl₃) Î´ 10.37 (s, 1H), 8.76 (s, 1H), 7.90 (s, 1H), 7.34 (d, J=8.0 Hz, 1H), 7.24 (t, J=8.0 Hz, 1H), 7.02 (d, J=8.0 Hz, 1H), 6.53 (s, 1H), 4.38 (q, J=7.2, 14.4 Hz, 2H), 2.55 (s, 3H), 1.52 (s, 9H), 1.40 (t, J=7.2 Hz, 3H).

Step 2. tert-butyl 3-(5-(hydroxymethyl)-2-(methylthio)pyrimidin-4-ylamino)phenylcarbamate (3)

[Image Omitted]

Compound 2 (20.2 g, 50 mmol) was solved in anhydrous THF (500 mL) and cooled to âˆ’40Â° C. 2.0 M tetrahydro lithium aluminum (50 mL, 100 mmol) was added to the above reaction solution, warmed to the room temperature, and stirred for 2 hours. Under the ice bath, 20 mL methanol was added to quench the reaction. The reaction mixture was then treated with saturated NaHCO₃solution (75 mL) to separate out aluminum hydroxide. The resulted mixture was filtered by diatomite under reduced pressure, then the solvent was concentrated and separated by column chromatography to yield a yellow solid (10.33 g, 57%).

¹H NMR (400 Hz, CDCl₃) Î´ 8.02 (s, 1H), 7.86 (s, 1H), 7.80 (s, 1H), 7.36 (dd, J=1.2, 8.0 Hz, 1H), 7.22 (t, J=8.0 Hz, 1H), 6.95 (dd, J=1.2, 8.0 Hz, 1H), 6.52 (s, 1H), 4.61 (s, 2H), 2.52 (s, 3H), 1.52 (s, 9H).

Step 3. tert-butyl 3-(5-formyl-2-(methylthio)pyrimidin-4-ylamino)phenylcarbamate (4)

[Image Omitted]

To a solution of compound 3 (10.0 g, 27.6 mmol) in dichloromethane (300 mL) was added activated manganese-(IV) oxide (24.0 g, 276 mmol) at room temperature, and the mixture was stirred overnight, and then filtered by diatomite. The solvent was evaporated under increased pressure to yield a yellow solid (8.36 g, 84%).

¹H NMR (400 Hz, CDCl₃) Î´ 10.61 (s, 1H), 9.77 (s, 1H), 8.43 (s, 1H), 7.98 (s, 1H), 7.36 (dd, J=0.8, 8.0 Hz, 1H), 7.25-7.29 (m, 1H), 7.03 (dd, J=1.2, 8.0 Hz, 1H), 6.51 (s, 1H), 2.59 (s, 3H), 1.53 (s, 9H).

Step 4. tert-butyl 3-(5-((methylamino)methyl)-2-(methylthio)pyrimidin-4-ylamino)Phenyl Carbamate (5)

[Image Omitted]

To a solution of compound 4 (7.21 g, 20.0 mmol) in methanol (200 mL) which was cooled to 0Â° C. were added sodium acetate (8.2 g, 100 mmol) and methanaminium chloride (6.75 g, 100 mmol), the mixture was move to room temperature and stirred for 1 h. The mixture was cooled to 0Â° C. again and NaBH4 (1.51 g, 40.0 mmol) was added. The reaction mixture was move to room temperature and stirred overnight. Then, the solution was concentrated, extracted by DCM, washed by saturated NaHCO₃solution, washed by saturated brine, dried by anhydrous Na₂SO₄, and purified by group chromatography to yield a white solid (5.25 g, 71%).

¹H NMR (400 Hz, CDCl₃) Î´ 10.12 (s, 1H), 7.89 (s, 1H), 7.78 (s, 1H), 7.35 (d, J=8.8 Hz, 1H), 7.21 (t, J=8.0 Hz, 1H), 6.97 (dd, J=1.2, 8.0 Hz, 1H), 6.50 (s, 1H), 3.74 (s, 2H), 3.55 (s, 3H), 2.44 (d, J=0.4 Hz, 3H), 1.52 (s, 9H).

Step 5. tert-butyl 3-(3-methyl-7-(methylthio)-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenylcarbamate (6)

[Image Omitted]

To a solution of compound 5 (5.20 g, 13.8 mmol) in THF (140 mL) were added DIEA (8 mL, 55.2 mmol) and 0.2 M triphosgene (25 mL, 5.05 mmol) at 0Â° C., and the mixture was stirred at room temperature for 1 h. The solvent was concentrated, extracted by DCM, washed by water for three times, washed by saturated brine for one time, dried by anhydrous Na₂SO₄, evaporated under reduced pressure, and then recrystallized by ethyl acetate to yield a white solid (4.71 g, 85%).

¹H NMR (400 Hz, CDCl₃) Î´ 8.10 (s, 1H), 7.44 (s, 1H), 7.34 (t, J=8.0 Hz, 1H), 7.23 (d, J=7.2 Hz, 1H), 6.90 (d, J=8.0 Hz, 1H), 6.55 (s, 1H), 4.46 (s, 2H), 3.08 (s, 3H), 2.14 (s, 3H), 1.50 (s, 9H).

Step 6. tert-butyl 3-(3-methyl-7-(methylsulfonyl)-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenylcarbamate (7)

[Image Omitted]

To a solution of compound 6 (4.0 g, 10.0 mmol) in dichloromethane (100 mL) was added 85% m-chloroperbenzoic acid (6.1 g, 30.0 mmol) in batches at 0Â° C. The reaction mixture was stirred for 3 h at room temperature, diluted by DCM, washed by saturated NaHCO₃solution for three times, washed by saturated brine for one time, dried by anhydrous Na₂SO₄, evaporated the solvent under reduced pressure, and then recrystallized by ethyl acetate to yield a white solid (3.90 g, 90% yield).

¹H NMR (400 Hz, CDCl₃) Î´ 8.45 (s, 1H), 7.58 (s, 1H), 7.35 (t, J=8.0 Hz, 1H), 7.15 (dd, J=1.2, 8.0 Hz, 1H), 6.89 (dd, J=1.2, 8.0 Hz, 1H), 6.67 (s, 1H), 4.62 (s, 2H), 3.11 (s, 3H), 2.98 (s, 3H), 1.48 (s, 9H).

Step 7. tert-butyl 3-(3-methyl-7-(methylamino)-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1-(2H)-yl)phenylcarbamate (8)

[Image Omitted]

To a solution of compound 7 (260 mg, 0.6 mmol) in 1,4-Dioxane (1 ml), were added Methylamine methylamine hydrochloride (405 mg, 10 eq), CH₃COONa (492 mg, 10 eq). The reaction mixture was heated to 100Â° C. for reacting in a sealed tube for 24 h. The reaction mixture was diluted by DCM, washed by saturated NaHCO₃, washed by saturated brine, dried by anhydrous Na₂SO₄, evaporated the solvent under reduced pressure, and then purified by column chromatography to yield a whilt solid (205 mg, 89%).

¹H NMR (400 Hz, CDCl₃) Î´ 7.93 (s, 1H), 7.36 (s, 1H), 7.33 (t, J=8.0 Hz, 1H), 7.28 (s, 1H), 6.90 (d, J=8.0 Hz, 1H), 6.55 (s, 1H), 4.84 (d, J=4.4 Hz, 1H), 4.37 (s, 2H), 3.06 (s, 3H), 2.76 (s, 3H), 1.49 (s, 9H)

Step 8. 1-(3-aminophenyl)-3-methyl-7-(methylamino)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one (9)

[Image Omitted]

To a solution of compound 8 (205 mg, 0.53 mmol) in DCM (1 ml) was added TFA (0.4 ml, 10 eq). The reaction mixture was stirred for 4 h at room temperature, diluted by DCM, washed by saturated NaHCO₃solution, washed by saturated brine, dried by anhydrous Na₂SO₄, and then evaporated the solvent under reduced pressure to yield a yellow solid (140 mg, 93%).

Step 9. N-(3-(3-methyl-7-(methylamino)-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide (C-EGF21) (10)

[Image Omitted]

To a solution of compound 9 (128 mg, 0.45 mmol) in dichloromethane (2 ml), were added diisopropylethylamine (65 Î¼l, 1.0 eq). The reaction mixture was cooled to 0Â° C., and then added acryloyl chloride (37 Î¼l, 1.0 eq) slowly, stirred for 1 h at room temperature, evaporated the solvent under reduced pressure, and then purified by column chromatography to yield a white solid (114 mg, 75%).

¹H NMR (400 Hz, DMSO-d₆) Î´ 10.23 (s, 1H), 8.01 (s, 1H), 7.61 (d, J=8.0 Hz, 1H), 7.55 (s, 1H), 7.36 (t, J=8.0 Hz, 1H), 6.91 (d, J=7.6 Hz, 1H), 6.71 (s, 1H), 6.43 (dd, J=10.0, 16.8 Hz, 1H), 6.25 (d, J=16.8 Hz, 1H), 5.76 (d, J=10.4 Hz, 1H), 4.37 (s, 2H), 2.93 (s, 3H), 2.59 (s, 3H).

LCMS (ESI): m/z 339.1 [M+H]⁺.

Example 2N-(3-(3-methyl-2-oxo-7-(phenylamino)-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide (C-EGF10)

[Image Omitted]

This compound was synthesized with similar procedures to that of example 1.

¹H NMR (400 Hz, DMSO-d₆) Î´ 10.30 (s, 1H), 9.41 (s, 1H), 8.18 (s, 1H), 7.43 (d, J=8.0 Hz, 1H), 7.66 (s, 1H), 7.45 (t, J=8.0 Hz, 1H), 7.27 (d, J=8.0 Hz, 2H), 6.99 (d, J=8.0 Hz, 1H), 6.93 (t, J=7.6 Hz, 2H), 6.75 (t, J=7.2 Hz, 1H), 6.42 (dd, J=10.4, 16.8 Hz, 1H), 6.24 (d, J=16.8 Hz, 1H), 5.75 (d, J=10.4 Hz, 1H), 4.48 (s, 2H), 2.97 (s, 3H).

LCMS (ESI): m/z 401.1 [M+H]⁺.

Example 3N-(3-(3-methyl-7-(4-methylpiperazin-1-yl)-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide (C-EGF19)

[Image Omitted]

This compound was synthesized with similar procedures to that of example 1.

¹H NMR (400 Hz, DMSO-d₆) Î´ 8.25 (s, 1H), 7.95 (s, 1H), 7.53 (s, 1H), 7.38 (d, J=7.6 Hz, 1H), 7.23-7.27 (m, 1H), 6.88 (d, J=7.6 Hz, 1H), 6.32 (d, J=16.4 Hz, 1H), 6.12 (dd, J=10.0, 16.4 Hz, 1H), 5.64 (d, J=10.0 Hz, 1H), 4.41 (s, 2H), 3.52 (m, 4H), 3.10 (s, 3H), 2.30 (m, 4H), 2.25 (s, 3H).

LCMS (ESI): m/z 408.2 [M+H]⁺.

Example 4N-(3-(7-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide (C-EGF06)

[Image Omitted]

tert-butyl 3-(7-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1pyrimidin-1(2H)-yl)phenylcarbamate (11)

[Image Omitted]

To a solution of compound 7 (260 mg, 0.6 mmol) in butan-2-ol (1 mL) were added 2-methoxy-4-(4-methylpiperazin-1-yl)aniline (133 mg, 0.6 mmol) and trifluoroacetic acid (48 Î¼L, 0.6 mmol). The reaction mixture was heated to 110Â° C. and reacted in a sealed tube for 24 h, diluted by DCM, washed by saturated NaHCO₃solution, washed by saturated brine, dried by anhydrous Na₂SO₄, evaporated the solvent under reduced pressure, and then purified by column chromatography to yield a yellow solid (151 mg, 44%).

¹H NMR (400 Hz, CDCl₃) Î´ 7.99 (s, 1H), 7.48 (d, J=7.5 Hz, 1H), 7.44 (s, 1H), 7.41 (t, J=8.0 Hz, 1H), 7.35 (s, 1H), 6.97 (d, J=7.5 Hz, 1H), 6.63 (s, 1H), 6.42 (d, J=2.0 Hz, 1H), 6.16 (d, J=6.4 Hz, 1H), 4.42 (s, 2H), 3.80 (s, 3H), 3.22 (m, 4H), 3.08 (s, 3H), 2.79 (m, 4H), 1.47 (s, 9H).

The other steps are similar to that of example 1.

N-(3-(7-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide (C-EGF06)

[Image Omitted]

¹H NMR (400 Hz, DMSO-d₆) Î´ 10.31 (s, 1H), 8.11 (s, 1H), 7.81 (d, J=7.6 Hz, 1H), 7.56 (s, 1H), 7.48 (s, 1H), 7.43 (t, J=8.0 Hz, 1H), 7.27 (d, J=8.4 Hz, 1H), 6.95 (d, J=8.0 Hz, 1H), 6.51 (s, 1H), 6.44 (dd, J=10.0, 16.8 Hz, 1H), 6.25 (d, J=16.8 Hz, 1H), 6.02 (d, J=8.0 Hz, 1H), 5.76 (d, J=10.0 Hz, 1H), 4.46 (s, 2H), 3.76 (s, 3H), 2.99 (m, 4H), 2.96 (s, 3H), 2.50 (m, 4H), 2.22 (s, 3H).

LCMS (ESI): m/z 529.2 [M+H]⁺.

Example 5N-(3-(7-(2-methoxy-4-(piperidin-1-yl)phenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide (C-EGF11)

[Image Omitted]

This compound was synthesized with similar procedures to that of example 4.

¹H NMR (400 Hz, DMSO-d₆) Î´ 10.29 (s, 1H), 8.11 (s, 1H), 7.82 (d, J=8.0 Hz, 1H), 7.56 (s, 1H), 7.46 (s, 1H), 7.43 (t, J=8.0 Hz, 1H), 7.25 (d, J=8.0 Hz, 1H), 6.95 (d, J=8.0 Hz, 1H), 6.49 (d, J=1.6 Hz, 1H), 6.43 (dd, J=8.0, 16.8 Hz, 1H), 6.25 (dd, J=1.6, 16.8 Hz, 1H), 6.02 (d, J=7.2 Hz, 1H), 5.76 (d, J=11.2 Hz, 1H), 4.46 (s, 2H), 3.75 (s, 3H), 2.96 (m, 7H), 1.59 (m, 4H), 1.49-1.50 (m, 2H).

LCMS (ESI): m/z 514.2 [M+H]⁺.

Example 6N-(3-(7-(2-methoxy-4-(pyrrolidin-1-yl)phenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide (C-EGF12)

[Image Omitted]

This compound was synthesized with similar procedures to that of example 4.

¹H NMR (400 Hz, DMSO-d₆) Î´ 10.31 (s, 1H), 8.07 (s, 1H), 7.77 (d, J=8.0 Hz, 1H), 7.59 (s, 1H), 7.41 (t, J=8.0 Hz, 1H), 7.15 (d, J=8.0 Hz, 1H), 6.95 (d, J=8.0 Hz, 1H), 6.44 (dd, J=10.0, 16.8 Hz, 1H), 6.25 (d, J=16.4 Hz, 1H), 6.10 (s, 1H), 5.76 (d, J=10.0 Hz, 2H), 4.44 (s, 2H), 3.74 (s, 3H), 3.14 (m, 4H), 2.96 (s, 3H), 1.92 (m, 4H).

LCMS (ESI): m/z 500.2 [M+H]⁺.

Example 7N-(3-(7-(2-methoxy-4-morpholinophenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide (C-EGF08)

[Image Omitted]

This compound was synthesized with similar procedures to that of example 4.

¹H NMR (400 Hz, DMSO-d₆) Î´ 10.30 (s, 1H), 8.12 (s, 1H), 7.81 (d, J=6.8 Hz, 1H), 7.56 (s, 1H), 7.50 (s, 1H), 7.43 (t, J=8.0 Hz, 1H), 7.28 (d, J=10.0 Hz, 1H), 6.96 (d, J=10.0 Hz, 1H), 6.52 (d, J=2.0 Hz, 1H), 6.43 (dd, J=10.0, 16.8 Hz, 1H), 6.22-6.27 (m, 1H), 6.02 (d, J=8.0 Hz, 1H), 5.74-5.77 (m, 1H), 4.46 (s, 2H), 3.76 (s, 3H), 3.71 (t, J=4.4 Hz, 4H), 2.96 (m, 7H).

LCMS (ESI): m/z 516.2 [M+H]⁺.

Example 8N-(3-(7-(2-methoxy-4-thiomorpholinophenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide (C-EGF09)

[Image Omitted]

This compound was synthesized with similar procedures to that of example 4.

¹H NMR (400 Hz, DMSO-d₆) Î´ 10.31 (s, 1H), 8.11 (s, 1H), 7.82 (d, J=7.6 Hz, 1H), 7.56 (s, 1H), 7.51 (s, 1H), 7.43 (t, J=8.0 Hz, 1H), 7.27 (d, J=8.8 Hz, 1H), 6.97 (d, J=7.6 Hz, 1H), 6.49 (d, J=2.0 Hz, 1H), 6.43 (dd, J=10.0, 16.8 Hz, 1H), 6.26 (dd, J=2.0, 16.8 Hz, 1H), 6.02 (d, J=7.6 Hz, 1H), 5.75-5.77 (m, 1H), 4.45 (s, 2H), 3.76 (s, 3H), 3.33 (t, J=4.8 Hz, 4H), 2.96 (s, 3H), 2.65 (t, J=4.8 Hz, 4H).

LCMS (ESI): m/z 532.2 [M+H]⁺.

Example 9N-(3-(7-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide (C-EGF14)

[Image Omitted]

This compound was synthesized with similar procedures to that of example 4.

¹H NMR (400 Hz, DMSO-d₆) Î´ 10.28 (s, 1H), 8.11 (s, 1H), 7.82 (d, J=8.0 Hz, 1H), 7.55 (s, 1H), 7.47 (s, 1H), 7.42 (t, J=8.0 Hz, 1H), 7.24 (d, J=8.8 Hz, 1H), 6.95 (d, J=8.0 Hz, 1H), 6.49 (d, J=2.0 Hz, 1H), 6.43 (dd, J=10.0, 16.8 Hz, 1H), 6.25 (dd, J=1.6, 16.8 Hz, 1H), 6.02 (d, J=7.2 Hz, 1H), 5.76 (dd, J=1.6, 10.0 Hz, 1H), 4.46 (s, 2H), 3.75 (s, 3H), 3.53 (d, J=12.0 Hz, 2H), 2.96 (s, 3H), 2.50-2.55 (m, 6H), 2.21-2.30 (m, 5H), 2.14 (s, 3H), 1.80 (d, J=11.2 Hz, 2H), 1.42-1.50 (m, 2H).

LCMS (ESI): m/z 612.3 [M+H]⁺.

Example 10N-(3-(7-(4-(4-(dimethylamino)piperidin-1-yl)-2-methoxyphenylamino)-3-methyl-2-oxo-3,4-dihy dropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide (C-EGF13)

[Image Omitted]

This compound was synthesized with similar procedures to that of example 4.

¹H NMR (400 Hz, DMSO-d₆) Î´ 10.34 (s, 1H), 8.11 (s, 1H), 7.84 (d, J=7.6 Hz, 1H), 7.55 (s, 1H), 7.48 (s, 1H), 7.42 (t, J=8.0 Hz, 1H), 7.25 (d, J=8.4 Hz, 1H), 6.95 (d, J=7.2 Hz, 1H), 6.51 (s, 1H), 6.45 (dd, J=10.0, 17.2 Hz, 1H), 6.25 (d, J=16.8 Hz, 1H), 6.04 (s, 1H), 5.76 (d, J=9.6 Hz, 1H), 4.46 (s, 2H), 3.75 (s, 3H), 3.56 (d, J=12.4 Hz, 2H), 3.35 (s, 3H), 2.87 (m, 1H), 2.49-2.56 (m, 2H), 2.34 (s, 6H), 1.86 (d, J=10.4 Hz, 2H), 1.46-1.55 (m, 2H).

LCMS (ESI): m/z 557.2 [M+H]⁺.

Example 11N-(3-(7-(2-methoxy-4-(4-methyl-1,4-diazepan-1-yl)phenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide (C-EGF17)

[Image Omitted]

This compound was synthesized with similar procedures to that of example 4.

¹H NMR (400 Hz, DMSO-d₆) Î´ 10.30 (s, 1H), 8.19 (s, 1H), 7.85 (s, 1H), 7.69-7.70 (m, 2H), 7.51 (t, J=8.0 Hz, 1H), 7.45 (t, J=8.0 Hz, 1H), 6.96-6.99 (m, 2H), 6.40-6.46 (m, 2H), 6.24 (dd, J=1.6, 16.8 Hz, 1H), 5.75 (dd, J=1.6, 10.0 Hz, 1H), 4.50 (s, 2H), 3.33 (m, 7H), 2.98 (s, 3H), 2.74 (t, J=4.4 Hz, 4H), 2.49 (m, 2H), 2.24 (s, 3H).

LCMS (ESI): m/z 543.2 [M+H]⁺.

Example 12(R)â€”N-(3-(7-(4-(3-(dimethylamino)pyrrolidin-1-yl)-2-methoxyphenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide (C-EGF15)

[Image Omitted]

This compound was synthesized with similar procedures to that of example 4.

¹H NMR (400 Hz, CDCl₃) Î´ 10.29 (s, 1H), 8.07 (s, 1H), 7.82 (d, J=8.0 Hz, 1H), 7.54 (s, 1H), 7.41 (t, J=8.0 Hz, 2H), 7.20 (d, J=8.4 Hz, 1H), 6.94 (d, J=7.6 Hz, 1H), 6.43 (dd, J=10.0, 16.8 Hz, 1H), 6.25 (dd, J=1.6, 16.8 Hz, 1H), 6.09 (d, J=2.0 Hz, 1H), 5.75 (dd, J=2.0, 10.0 Hz, 1H), 5.68 (d, J=6.4 Hz, 1H), 4.44 (s, 2H), 3.75 (s, 3H), 3.23-3.33 (m, 2H), 3.11-3.17 (m, 1H), 2.91-2.96 (m, 4H), 2.69-2.77 (m, 1H), 2.14 (s, 6H), 2.08-2.12 (m, 1H), 1.70-1.80 (m, 1H).

LCMS (ESI): m/z 543.2 [M+H]⁺.

Example 13(S)â€”N-(3-(7-(4-(3-(dimethylamino)pyrrolidin-1-yl)-2-methoxyphenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide (C-EGF16)

[Image Omitted]

This compound was synthesized with similar procedures to that of example 4.

¹H NMR (400 Hz, CDCl₃) Î´ 10.27 (s, 1H), 8.07 (s, 1H), 7.82 (d, J=7.2 Hz, 1H), 7.54 (s, 1H), 7.41 (t, J=8.0 Hz, 2H), 7.20 (d, J=8.4 Hz, 1H), 6.94 (d, J=7.6 Hz, 1H), 6.43 (dd, J=10.0, 17.2 Hz, 1H), 6.25 (dd, J=2.0, 16.8 Hz, 1H), 6.09 (d, J=2.4 Hz, 1H), 5.75 (dd, J=2.0, 10.0 Hz, 1H), 5.69 (s, 1H), 4.44 (s, 2H), 3.75 (s, 3H), 3.23-3.33 (m, 2H), 3.11-3.17 (m, 1H), 2.92-2.96 (m, 4H), 2.73-2.78 (m, 1H), 2.21 (s, 6H), 2.08-2.15 (m, 1H), 1.71-1.81 (m, 1H).

LCMS (ESI): m/z 543.2 [14+H]⁺.

Example 14N-(3-(7-(4-(4-acetylpiperazin-1-yl)-2-methoxyphenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide (C-EGF20)

[Image Omitted]

This compound was synthesized with similar procedures to that of example 4.

¹H NMR (400 Hz, DMSO-d₆) Î´ 10.28 (s, 1H), 8.12 (s, 1H), 7.82 (d, J=7.6 Hz, 1H), 7.55 (s, 1H), 7.50 (s, 1H), 7.43 (t, J=8.0 Hz, 1H), 7.28 (d, d, J=8.8 Hz, 1H), 6.96 (d, J=7.6 Hz, 1H), 6.55 (d, d, J=1.6 Hz, 1H), 6.43 (dd, J=10.0, 16.8 Hz, 1H), 6.25 (dd, J=2.0, 17.2 Hz, 1H), 6.04 (d, J=8.8 Hz, 1H), 5.75 (dd, J=2.0, 10.0 Hz, 1H), 4.46 (s, 2H), 3.77 (s, 3H), 3.52-3.56 (m, 4H), 3.00 (t, J=4.8 Hz, 2H), 2.96 (s, 3H), 2.93 (t, J=4.8 Hz, 2H), 2.04 (s, 3H).

LCMS (ESI): m/z 557.2 [M+H]⁺.

Example 15N-(3-(7-(4-(dimethylamino)-2-methoxyphenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide (C-EGF23)

[Image Omitted]

This compound was synthesized with similar procedures to that of example 4.

¹H NMR (400 Hz, DMSO-d₆) Î´ 10.28 (s, 1H), 8.09 (s, 1H), 7.79 (d, J=8.8 Hz, 1H), 7.57 (s, 1H), 7.42 (t, J=8.0 Hz, 2H), 7.22 (d, J=8.8 Hz, 1H), 6.95 (d, J=8.0 Hz, 1H), 6.43 (dd, J=10.0, 16.8 Hz, 1H), 6.30 (d, J=2.4 Hz, 1H), 6.25 (dd, J=2.0, 16.8 Hz, 1H), 5.87 (d, J=7.6 Hz, 1H), 5.75 (dd, J=2.0, 10.0 Hz, 1H), 4.45 (s, 2H), 3.76 (s, 3H), 2.96 (s, 3H), 2.78 (s, 6H).

LCMS (ESI): m/z 474.2 [M+H]⁺.

Example 16N-(3-(7-(2-fluoro-4-(4-methylpiperazin-1-yl)phenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide (C-EGF18)

[Image Omitted]

This compound was synthesized with similar procedures to that of example 4.

¹H NMR (400 Hz, CDCl₃) Î´ 10.30 (s, 1H), 8.19 (s, 1H), 7.86 (s, 1H), 7.69-7.70 (m, 2H), 7.51 (t, J=8.0 Hz, 1H), 7.45 (t, J=8.0 Hz, 1H), 6.96-6.99 (m, 2H), 6.40-6.47 (m, 2H), 6.24 (dd, J=2.0, 17.2 Hz, 1H), 5.75 (dd, J=2.0, 10.0 Hz, 1H), 4.50 (s, 2H), 2.98 (s, 3H), 2.74 (t, J=4.4 Hz, 4H), 2.50 (m, 4H), 2.24 (s, 3H).

LCMS (ESI): m/z 517.2 [M+H]⁺.

Example 17N-(3-(7-(2-methoxy-4-(2-methoxyethoxy)phenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide (C-EGF22)

[Image Omitted]

This compound was synthesized with similar procedures to that of example 4.

¹H NMR (400 Hz, CDCl₃) Î´ 10.30 (s, 1H), 8.12 (s, 1H), 7.75 (d, J=7.6 Hz, 1H), 7.61 (s, 1H), 7.54 (s, 1H), 7.43 (t, J=8.0 Hz, 1H), 7.30 (d, J=8.4 Hz, 1H), 6.96 (d, J=7.6 Hz, 1H), 6.52 (d, J=2.4 Hz, 1H), 6.43 (dd, J=10.0, 16.8 Hz, 1H), 6.25 (dd, J=1.2, 16.8 Hz, 1H), 6.04 (d, J=8.4 Hz, 1H), 5.75 (d, J=11.6 Hz, 1H), 4.46 (s, 2H), 3.97 (t, J=4.4 Hz, 2H), 3.76 (s, 3H), 3.61 (t, J=4.4 Hz, 2H), 3.30 (s, 3H), 2.96 (s, 3H).

LCMS (ESI): m/z 505.0 [M+H]⁺.

Example 18N-(3-(3-isopropyl-7-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-2-oxo-3,4-dihydropyri mido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide (C-EGF24)

[Image Omitted]

This compound was synthesized with similar procedures to that of example 4.

¹H NMR (400 Hz, DMSO-d₆) Î´ 10.28 (s, 1H), 8.14 (s, 1H), 7.79 (d, J=7.2 Hz, 1H), 7.57 (s, 1H), 7.46 (s, 1H), 7.42 (t, J=8.0 Hz, 1H), 7.30 (d, J=8.0 Hz, 1H), 6.97 (d, J=8.0 Hz, 1H), 6.51 (s, 1H), 6.43 (dd, J=10.0, 16.8 Hz, 1H), 6.25 (d, J=16.8 Hz, 1H), 6.04 (d, J=6.0 Hz, 1H), 5.76 (d, J=10.0 Hz, 1H), 4.54-4.57 (m, 1H), 4.37 (s, 2H), 3.76 (s, 3H), 2.99 (m, 4H), 2.42 (m, 4H), 2.21 (s, 3H), 1.19 (d, J=6.4 Hz, 6H).

LCMS (ESI): m/z 557.2 [M+H]⁺.

Example 19N-(3-(7-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-3-(4-methoxyphenyl)-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide (C-EGF25)

[Image Omitted]

This compound was synthesized with similar procedures to that of example 4.

¹H NMR (400 Hz, DMSO-d₆) Î´ 10.33 (s, 1H), 8.15 (s, 1H), 7.81 (d, J=7.2 Hz, 1H), 7.66 (s, 1H), 7.56 (s, 1H), 7.45 (t, J=8.0 Hz, 1H), 7.36 (d, J=8.4 Hz, 2H), 7.30 (d, J=8.8 Hz, 1H), 7.05 (d, J=7.6 Hz, 1H), 6.97 (d, J=8.4 Hz, 2H), 6.52 (s, 1H), 6.44 (dd, J=10.0, 17.2 Hz, 1H), 6.26 (d, J=16.8 Hz, 1H), 6.05 (s, 1H), 5.76 (d, J=9.6 Hz, 1H), 4.81 (s, 2H), 3.77 (s, 6H), 3.01 (m, 4H), 2.44 (m, 4H), 2.23 (s, 3H).

LCMS (ESI): m/z 621.2 [M+H]⁺.

Example 20N-(3-(3-cyclopropyl-7-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide (C-EGF26)

[Image Omitted]

This compound was synthesized with similar procedures to that of example 4.

¹H NMR (400 Hz, DMSO-d₆) Î´ 10.29 (s, 1H), 8.12 (s, 1H), 7.81 (d, J=8.4 Hz, 1H), 7.56 (s, 1H), 7.48 (s, 1H), 7.43 (t, J=8.0 Hz, 1H), 7.27 (d, J=8.8 Hz, 1H), 6.96 (d, J=8.0 Hz, 1H), 6.50 (d, J=2.4 Hz, 1H), 6.43 (dd, J=10.0, 16.8 Hz, 1H), 6.25 (dd, J=2.0, 16.8 Hz, 1H), 6.03 (d, J=7.6 Hz, 1H), 5.76 (dd, J=2.0, 10.0 Hz, 1H), 4.43 (s, 2H), 3.76 (s, 3H), 2.99 (t, J=4.8 Hz, 4H), 2.65-2.70 (m, 1H), 2.42 (t, J=4.8 Hz, 4H), 2.21 (s, 3H), 0.73-0.79 (m, 2H), 0.66-0.70 (m, 2H).

LCMS (ESI): m/z 555.2 [M+H]⁺.

Example 21N-(3-(3-methyl-7-(4-(4-methylpiperazin-1-yl)phenylamino)-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide (Ã—001)

[Image Omitted]

This compound was synthesized with similar procedures to that of example 4.

¹H NMR (400 MHz, DMSO) Î´ 10.31 (s, 1H), 9.17 (s, 1H), 8.13 (s, 1H), 7.84 (d, J=8.0 Hz, 1H), 7.56 (s, 1H), 7.44 (t, J=8.0 Hz, 1H), 7.12 (d, J=7.2 Hz, 2H), 6.96 (d, J=7.6 Hz, 1H), 6.53 (d, J=8.0 Hz, 2H), 6.43 (dd, J=16.4, 9.6 Hz, 1H), 6.25 (d, J=16.4 Hz, 1H), 5.76 (d, J=10.0 Hz, 1H), 4.46 (s, 2H), 2.97 (s, 3H), 2.92 (s, 4H), 2.41 (s, 4H), 2.20 (s, 3H).

LCMS (ESI): m/z 499.2 [M+H]⁺.

Example 22N-(3-(3-methyl-2-oxo-7-(4-(piperidin-1-yl)phenylamino)-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide (Ã—002)

[Image Omitted]

This compound was synthesized with similar procedures to that of example 4.

¹H NMR (400 MHz, DMSO) Î´ 10.31 (s, 1H), 9.16 (s, 1H), 8.12 (s, 1H), 7.85 (d, J=7.2 Hz, 1H), 7.56 (s, 1H), 7.44 (t, J=8.0 Hz, 1H), 7.10 (d, J=7.6 Hz, 2H), 6.96 (d, J=7.2 Hz, 1H), 6.52 (d, J=8.0 Hz, 2H), 6.43 (dd, J=16.8, 9.6 Hz, 1H), 6.25 (d, J=17.6 Hz, 1H), 5.75 (d, J=10.0 Hz, 1H), 4.45 (s, 2H), 2.96 (s, 3H), 2.90 (s, 4H), 1.57 (s, 4H), 1.47 (d, J=5.2 Hz, 2H).

LCMS (ESI): m/z 484.1 [M+H]⁺.

Example 23N-(3-(3-methyl-7-(4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenylamino)-2-oxo-3,4-dihydro pyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide (Ã—003)

[Image Omitted]

This compound was synthesized with similar procedures to that of example 4.

¹H NMR (400 MHz, DMSO) Î´ 10.31 (s, 1H), 9.15 (s, 1H), 8.12 (s, 1H), 7.85 (d, J=8.8 Hz, 1H), 7.55 (s, 1H), 7.43 (t, J=8.0 Hz, 1H), 7.10 (d, J=8.4 Hz, 2H), 6.96 (d, J=8.4 Hz, 1H), 6.53 (d, J=8.0 Hz, 2H), 6.43 (dd, J=17.0, 9.0 Hz, 1H), 6.23-6.27 (m, 1H), 5.76 (d, J=11.6 Hz, 1H), 4.45 (s, 2H), 3.47 (d, J=11.6 Hz, 2H), 3.33 (s, 3H), 2.97 (s, 3H), 2.33-2.50 (m, 7H), 2.21 (s, 4H), 1.79 (d, J=11.6 Hz, 2H), 1.41-1.49 (m, 2H).

LCMS (ESI): m/z 582.2 [14+H]⁺.

Example 24N-(3-(7-(4-(4-(dimethylamino)piperidin-1-yl)phenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide (Ã—004)

[Image Omitted]

This compound was synthesized with similar procedures to that of example 4.

¹H NMR (400 MHz, DMSO) Î´ 10.31 (s, 1H), 9.17 (s, 1H), 8.12 (s, 1H), 7.85 (d, J=7.6 Hz, 1H), 7.55 (s, 1H), 7.44 (t, J=8.0 Hz, 1H), 7.10 (d, J=6.0 Hz, 2H), 6.96 (d, J=7.6 Hz, 1H), 6.53 (d, J=7.2 Hz, 2H), 6.39 (dd, J=16.8, 10.4 Hz, 1H), 6.25 (d, J=16.4 Hz, 1H), 5.76 (d, J=9.6 Hz, 1H), 4.45 (s, 2H), 3.45 (d, J=11.6 Hz, 2H), 2.96 (s, 3H), 2.45 (d, J=11.2 Hz, 2H), 2.18 (s, 7H), 1.78 (d, J=11.2 Hz, 2H), 1.41-1.46 (m, 2H).

LCMS (ESI): m/z 527.2 [M+H]⁺

Example 25N-(3-(3-methyl-2-oxo-7-(4-thiomorpholinophenylamino)-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide (Ã—005)

[Image Omitted]

This compound was synthesized with similar procedures to that of example 4.

¹H NMR (400 MHz, DMSO) Î´ 10.31 (s, 1H), 9.20 (s, 1H), 8.13 (s, 1H), 7.84 (d, J=7.6 Hz, 1H), 7.56 (s, 1H), 7.44 (t, J=7.8 Hz, 1H), 7.13 (d, J=7.2 Hz, 2H), 6.96 (d, J=7.6 Hz, 1H), 6.53 (d, J=8.4 Hz, 2H), 6.43 (dd, J=17.0 Hz, 9.8 Hz, 1H), 6.25 (d, J=16.8 Hz, 1H), 5.76 (d, J=10.0 Hz, 1H), 4.46 (s, 2H), 3.25-3.26 (m, 4H), 2.97 (s, 3H), 2.62-2.64 (m, 4H).

LCMS (ESI): m/z 502.1 [M+H]⁺.

Example 26N-(3-(7-(2-isopropoxy-4-(4-methylpiperazin-1-yl)phenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide (Ã—006)

[Image Omitted]

This compound was synthesized with similar procedures to that of example 4.

¹H NMR (400 MHz, DMSO) Î´ 10.30 (s, 1H), 8.13 (s, 1H), 7.84 (d, J=8.0 Hz, 1H), 7.57 (s, 1H), 7.44 (t, J=8.0 Hz, 1H), 7.40 (s, 1H), 7.27 (d, J=9.2 Hz, 1H), 6.97 (d, J=7.6 Hz, 1H), 6.52 (s, 1H), 6.43 (dd, J=10.0, 16.8 Hz, 1H), 6.24 (d, J=16.8 Hz, 1H), 5.98 (d, J=8.0 Hz, 1H), 5.76 (d, J=10.4 Hz, 1H), 4.57-4.63 (m, 1H), 4.47 (s, 2H), 2.97 (m, 7H), 2.41 (m, 4H), 2.21 (s, 3H), 1.23 (d, J=6.0 Hz, 6H).

LCMS (ESI): m/z 557.3 [M+H]⁺.

Example 27N-(3-(3-methyl-7-(4-morpholinophenylamino)-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide (Ã—007)

[Image Omitted]

This compound was synthesized with similar procedures to that of example 4.

¹H NMR (400 MHz, DMSO) Î´ 10.31 (s, 1H), 9.19 (s, 1H), 8.13 (s, 1H), 7.83 (d, J=8.8 Hz, 1H), 7.56 (s, 1H), 7.44 (t, J=8.0 Hz, 1H), 7.14 (d, J=7.6 Hz, 2H), 6.96 (d, J=7.2 Hz, 1H), 6.54 (d, J=7.6 Hz, 2H), 6.43 (dd, J=17.2, 10.0 Hz, 1H), 6.24 (d, J=17.2 Hz, 1H), 5.76 (d, J=12.0 Hz, 1H), 4.46 (s, 2H), 3.70 (t, J=4.4 Hz, 4H), 2.97 (s, 3H), 2.90 (t, J=4.4 Hz, 4H).

LCMS (ESI): m/z 486.1 [M+H]⁺.

Example 28N-(3-(7-(2-methoxy-4-(2-morpholinoethoxy)phenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide (Ã—008)

[Image Omitted]

This compound was synthesized with similar procedures to that of example 4.

¹H NMR (400 MHz, CDCl₃) Î´ 8.18 (s, 1H), 8.00 (s, 1H), 7.85 (d, J=8.4 Hz, 1H), 7.39-7.43 (m, 4H), 6.99 (d, J=7.6 Hz, 1H), 6.37-6.39 (m, 2H), 6.33 (s, 1H), 6.18-6.24 (m, 1H), 6.07-6.10 (m, 1H), 5.67 (d, J=10.4 Hz, 1H), 4.45 (s, 2H), 4.10 (s, 2H), 3.80 (s, 4H), 3.77 (s, 3H), 3.09 (s, 3H), 2.85 (s, 2H), 2.68 (s, 4H).

LCMS (ESI): m/z 560.1 [M+H]⁺.

Example 29N-(3-(7-(2-ethoxy-4-(4-methylpiperazin-1-yl)phenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide (Ã—009)

[Image Omitted]

This compound was synthesized with similar procedures to that of example 4.

¹H NMR (400 MHz, CDCl₃) Î´ 8.28 (s, 1H), 7.99 (s, 1H), 7.93 (d, J=7.6 Hz, 1H), 7.48 (s, 1H), 7.40 (t, J=8.0 Hz, 2H), 7.28 (s, 1H), 6.96 (d, J=8.0 Hz, 1H), 6.38 (s, 1H), 6.34 (d, J=16.4 Hz, 1H), 6.18 (dd, J=16.8, 10.0 Hz, 1H), 6.10 (d, J=8.4 Hz, 1H), 5.65 (d, J=10.4 Hz, 1H), 4.42 (s, 2H), 4.00 (q, J=13.6, 6.8 Hz, 2H), 3.13 (s, 4H), 3.06 (s, 3H), 2.70 (s, 4H), 2.44 (s, 3H), 1.39 (t, J=6.8 Hz, 3H).

LCMS (ESI): m/z 543.2 [M+H]⁺.

Example 30N-(3-(3-methyl-7-(2-methyl-4-(4-methylpiperazin-1-yl)phenylamino)-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide (Ã—010)

[Image Omitted]

This compound was synthesized with similar procedures to that of example 4.

¹H NMR (400 MHz, CDCl₃) Î´ 8.35 (s, 1H), 7.97 (s, 1H), 7.62 (d, J=7.6 Hz, 1H), 7.45 (s, 1H), 7.27-7.33 (m, 2H), 6.91 (d, J=8.0 Hz, 1H), 6.64 (s, 1H), 6.56 (s, 1H), 6.49 (d, J=8.0 Hz, 1H), 6.33 (d, J=16.8 Hz, 1H), 6.17 (dd, J=16.8, 10.0 Hz, 1H), 5.64 (d, J=10.4 Hz, 1H), 4.44 (s, 2H), 3.14 (s, 4H), 3.10 (s, 3H), 2.65 (s, 4H), 2.41 (s, 3H), 2.14 (s, 3H).

LCMS (ESI): m/z 513.2 [M+H]⁺.

Example 31N-(3-(7-(3-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide (Ã—011)

[Image Omitted]

This compound was synthesized with similar procedures to that of example 4.

¹H NMR (400 MHz, DMSO) Î´ 10.30 (s, 1H), 9.13 (s, 1H), 8.15 (s, 1H), 7.79 (d, J=8.4 Hz, 1H), 7.58 (s, 1H), 7.42 (d, J=8.0 Hz, 1H), 6.91-6.97 (m, 2H), 6.86 (s, 1H), 6.39-6.46 (m, 2H), 6.24 (d, J=16.8 Hz, 1H), 5.75 (d, J=10.0 Hz, 1H), 4.46 (s, 2H), 3.58 (s, 3H), 2.96 (s, 3H), 2.79 (s, 4H), 2.39 (s, 4H), 2.19 (s, 3H).

LCMS (ESI): m/z 529.2 [M+H]⁺.

Example 32N-(3-(7-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-2-oxo-3-phenyl-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide (C-EGF27)

[Image Omitted]

This compound was synthesized with similar procedures to that of example 4.

¹H NMR (400 MHz, DMSO) Î´ 10.32 (s, 1H), 8.17 (s, 1H), 7.82 (d, J=8.0 Hz, 1H), 7.68 (s, 1H), 7.56 (s, 1H), 7.41-7.47 (m, 5H), 7.26-7.32 (m, 2H), 7.07 (d, J=7.6 Hz, 1H), 6.52 (d, J=2.0 Hz, 1H), 6.44 (dd, J=10.0, 16.8 Hz, 1H), 6.26 (dd, J=1.6, 16.8 Hz, 1H), 6.05 (d, J=7.2 Hz, 1H), 5.76 (d, J=11.6 Hz, 1H), 4.87 (s, 2H), 3.77 (s, 3H), 3.01 (m, 4H), 2.43 (m, 4H), 2.22 (s, 3H).

LCMS (ESI): m/z 591.2 [M+H]⁺.

Example 33N-(3-(3-benzyl-7-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide (C-EGF29)

[Image Omitted]

This compound was synthesized with similar procedures to that of example 4.

¹H NMR (400 MHz, DMSO) Î´ 10.30 (s, 1H), 8.08 (s, 1H), 7.84 (d, J=8.0 Hz, 1H), 7.60 (s, 1H), 7.49 (s, 1H), 7.45 (t, J=8.0 Hz, 1H), 7.33-7.41 (m, 4H), 7.26-7.32 (m, 1H), 7.02 (d, J=7.6 Hz, 1H), 6.50 (d, J=2.4 Hz, 1H), 6.43 (dd, J=10.0, 16.4 Hz, 1H), 6.25 (dd, J=2.0, 16.8 Hz, 1H), 6.03 (d, J=6.8 Hz, 1H), 5.76 (dd, J=2.0, 10.0 Hz, 1H), 4.64 (s, 2H), 4.40 (s, 2H), 3.75 (s, 3H), 2.99 (t, J=4.8 Hz, 4H), 2.42 (t, J=4.8 Hz, 4H), 2.21 (s, 3H).

LCMS (ESI): m/z 605.3 [M+H]⁺.

Example 34N-(3-(7-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-2-oxo-3-(4-phenoxyphenyl)-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide (C-EGF31)

[Image Omitted]

This compound was synthesized with similar procedures to that of example 4.

¹H NMR (400 MHz, DMSO) Î´ 10.32 (s, 1H), 8.17 (s, 1H), 7.81 (d, J=8.4 Hz, 1H), 7.67 (s, 1H), 7.56 (s, 1H), 7.40-7.47 (m, 5H), 7.30 (d, J=8.8 Hz, 1H), 7.16 (t, J=7.6 Hz, 1H), 7.04-7.07 (m, 5H), 6.52 (d, J=2.4 Hz, 1H), 6.44 (dd, J=10.0, 16.8 Hz, 1H), 6.25 (dd, J=2.0, 16.8 Hz, 1H), 6.04 (s, 1H), 5.76 (dd, J=2.0, 10.0 Hz, 1H), 4.86 (s, 2H), 3.77 (s, 3H), 3.00 (t, J=4.4 Hz, 4H), 2.43 (t, J=4.4 Hz, 4H), 2.22 (s, 3H).

LCMS (ESI): m/z 683.6 [M+H]⁺.

Example 35N-(3-(7-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-3-(naphthalen-1-yl)-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide (C-EGF28)

[Image Omitted]

This compound was synthesized with similar procedures to that of example 4.

¹H NMR (400 MHz, DMSO) Î´ 10.34 (s, 1H), 8.21 (s, 1H), 7.93-7.97 (m, 4H), 7.83 (d, J=8.4 Hz, 1H), 7.72 (s, 1H), 7.63 (dd, J=2.0, 8.4 Hz, 1H), 7.59 (s, 1H), 7.50-7.57 (m, 2H), 7.47 (t, J=8.0 Hz, 1H), 7.33 (d, J=8.8 Hz, 1H), 7.11 (d, J=7.6 Hz, 1H), 6.53 (d, J=2.0 Hz, 1H), 6.45 (dd, J=10.0, 16.8 Hz, 1H), 6.26 (dd, J=1.6, 16.8 Hz, 1H), 6.06 (d, J=8.0 Hz, 1H), 5.77 (dd, J=1.6, 10.0 Hz, 1H), 5.01 (s, 2H), 3.78 (s, 3H), 3.01 (m, 4H), 2.44 (m, 4H), 2.22 (s, 3H).

LCMS (ESI): m/z 641.2 [M+H]⁺.

Example 36N-(3-(3-(biphenyl-4-yl)-7-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide (C-EGF30)

[Image Omitted]

This compound was synthesized with similar procedures to that of example 4.

¹H NMR (400 MHz, DMSO) Î´ 10.33 (s, 1H), 8.19 (s, 1H), 7.83 (d, J=7.6 Hz, 1H), 7.69-7.74 (m, 5H), 7.46-7.58 (m, 6H), 7.37 (t, J=7.2 Hz, 1H), 7.32 (d, J=8.8 Hz, 1H), 7.09 (d, J=7.6 Hz, 1H), 6.52 (s, 1H), 6.45 (dd, J=10.0, 16.4 Hz, 1H), 6.26 (d, J=16.8 Hz, 1H), 6.06 (d, J=6.8 Hz, 1H), 5.77 (d, J=10.0 Hz, 1H), 4.92 (s, 2H), 3.77 (s, 3H), 3.01 (m, 4H), 2.43 (m, 4H), 2.22 (s, 3H).

LCMS (ESI): m/z 667.2 [M+H]⁺.

Example 37N-(3-(3-(4-(benzyloxy)phenyl)-7-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide (C-EGF32)

[Image Omitted]

This compound was synthesized with similar procedures to that of example 4.

¹H NMR (400 MHz, DMSO) Î´ 10.31 (s, 1H), 8.15 (s, 1H), 7.81 (d, J=8.4 Hz, 1H), 7.66 (s, 1H), 7.54 (s, 1H), 7.29-7.47 (m, 8H), 7.04-7.07 (m, 3H), 6.52 (d, J=2.0 Hz, 1H), 6.44 (dd, J=10.0, 16.8 Hz, 1H), 6.25 (dd, J=2.0, 16.8 Hz, 1H), 6.05 (d, J=8.0 Hz, 1H), 5.76 (dd, J=2.0, 10.0 Hz, 1H), 5.13 (s, 2H), 4.81 (s, 2H), 3.77 (s, 3H), 3.00 (t, J=4.4 Hz, 4H), 2.42 (t, J=4.4 Hz, 4H), 2.22 (s, 3H).

LCMS (ESI): m/z 698.2 [M+H]⁺.

Example 38N-(3-(7-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)propionamide (C-EGF34)

[Image Omitted]

This compound was synthesized with similar procedures to that of example 4.

¹H NMR (400 MHz, DMSO) Î´ 9.99 (s, 1H), 8.10 (s, 1H), 7.69 (d, J=8.4 Hz, 1H), 7.50 (s, 1H), 7.46 (s, 1H), 7.39 (t, J=8.0 Hz, 1H), 7.26 (d, J=8.4 Hz, 1H), 6.90 (d, J=8.0 Hz, 1H), 6.51 (d, J=2.4 Hz, 1H), 6.03 (d, J=7.6 Hz, 1H), 4.45 (s, 2H), 3.76 (s, 3H), 3.01 (t, J=4.4 Hz, 4H), 2.96 (s, 3H), 2.43 (t, J=4.4 Hz, 4H), 2.30 (q, J=7.2, 14.8 Hz, 2H), 2.22 (s, 3H), 1.06 (t, J=7.2 Hz, 3H).

LCMS (ESI): m/z 531.2 [M+H]⁺.

Example 391-(3-aminophenyl)-7-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-3-methyl-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one (C-EGF33)

[Image Omitted]

This compound was synthesized with similar procedures to that of example 4.

¹H NMR (400 Hz, CDCl₃) Î´ 7.99 (s, 1H), 7.61 (s, 1H), 7.46 (s, 1H), 7.28 (t, J=8.0 Hz, 2H), 6.78 (dd, J=2.0, 8.0 Hz, 1H), 6.67 (d, J=7.6 Hz, 1H), 6.61 (t, J=2.0 Hz, 1H), 6.45 (d, J=2.4 Hz, 1H), 6.21 (d, J=7.6 Hz, 1H), 4.42 (s, 2H), 3.81 (s, 3H), 3.13 (t, J=4.8 Hz, 4H), 3.09 (s, 3H), 2.64 (t, J=4.8 Hz, 4H), 2.29 (s, 3H).

LCMS (ESI): m/z 475.2 [M+H]⁺.

Example 40N-(3-(7-(cyclopropylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide (FLB-5-0226)

[Image Omitted]

This compound was synthesized with similar procedures to that of example 1.

¹H NMR (400 MHz, CDCl₃) Î´ 8.34 (s, 1H), 8.00 (s, 1H), 7.50 (s, 1H), 7.34 (d, J=8.4 Hz, 1H), 7.22-7.26 (m, 1H), 6.86 (d, J=6.4 Hz, 1H), 6.32 (d, J=16.8 Hz, 1H), 6.09 (dd, J=10.0, 16.8 Hz, 1H), 5.63 (d, J=10.4 Hz, 1H), 5.14 (s, 1H), 4.43 (s, 2H), 3.10 (s, 3H), 2.51 (m, 1H), 0.61 (m, 2H), 0.37 (m, 2H).

LCMS (ESI): m/z 365.2 [M+H]⁺

Example 41N-(3-(7-(isopropylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide (FLB-5-0227)

[Image Omitted]

This compound was synthesized with similar procedures to that of example 1.

¹H NMR (400 MHz, CDCl₃) Î´ 8.21 (s, 1H), 7.91 (s, 1H), 7.43-7.46 (m, 2H), 7.25-7.29 (m, 1H), 6.88 (d, J=7.6 Hz, 1H), 6.33 (d, J=16.8 Hz, 1H), 6.10 (dd, J=10.4, 17.2 Hz, 1H), 5.64 (d, J=11.2 Hz, 1H), 4.78 (d, J=6.4 Hz, 1H), 4.41 (s, 2H), 3.48 (m, 1H), 3.10 (s, 3H), 1.02 (d, 6H).

LCMS (ESI): m/z 367.2 [M+H]⁺

Example 42N-(3-(7-(cyclohexylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide (FLB-5-0230)

[Image Omitted]

This compound was synthesized with similar procedures to that of example 1.

¹H NMR (400 MHz, CDCl₃) Î´ 8.05 (s, 1H), 7.91 (s, 1H), 7.50 (s, 1H), 7.44 (d, J=8.0 Hz, 1H), 7.28 (t, J=8.0 Hz, 1H), 6.90 (d, J=7.2 Hz, 1H), 6.34 (d, J=17.6 Hz, 1H), 6.12 (dd, J=10.0, 16.8 Hz, 1H), 5.66 (dd, J=1.6, 10.0 Hz, 1H), 4.78 (d, J=7.6 Hz, 1H), 4.40 (s, 2H), 3.10 (s, 3H), 1.75-1.88 (m, 2H), 1.50-1.66 (m, 4H), 1.03-1.23 (m, 4H).

Example 43N-(3-(7-(ethylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide (FLB-5-0231)

[Image Omitted]

This compound was synthesized with similar procedures to that of example 1.

¹H NMR (400 Hz, CDCl₃) Î´ 8.47 (s, 1H), 7.92 (s, 1H), 7.49 (s, 1H), 7.35 (d, J=8.8 Hz, 1H), 7.23 (t, J=8.0 Hz, 1H), 6.85 (d, J=7.6 Hz, 1H), 6.32 (dd, J=6.8, 16.8 Hz, 1H), 6.08-6.14 (m, 1H), 5.61 (d, J=10.4 Hz, 1H), 4.91 (m, 1H), 4.41 (s, 2H), 3.07-3.18 (m, 5H), 0.85 (t, J=7.2 Hz, 3H).

LCMS (ESI): m/z 353.1 [M+H]⁺

Example 44N-(3-(3-methyl-7-(2-morpholinoethylamino)-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide (FLB-5-0235)

[Image Omitted]

This compound was synthesized with similar procedures to that of example 1. LCMS (ESI): m/z 438.1 [M+H]⁺

Example 45N-(3-(7-(benzylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide (FLB-5-0238)

[Image Omitted]

This compound was synthesized with similar procedures to that of example 1.

LCMS (ESI): m/z 415.1 [M+H]⁺

Example 46N-(3-(3-(3-chlorophenyl)-7-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide (C-EGF35)

[Image Omitted]

This compound was synthesized with similar procedures to that of example 4.

¹H NMR (400 MHz, DMSO) Î´ 10.32 (s, 1H), 8.17 (s, 1H), 7.82 (d, J=6.8 Hz, 1H), 7.68 (s, 1H), 7.58 (s, 2H), 7.45 (m, 3H), 7.34 (d, J=7.2 Hz, 1H), 7.30 (d, J=8.8 Hz, 1H), 7.08 (d, J=7.6 Hz, 1H), 6.52 (s, 1H), 6.47 (dd, J=10.0, 16.8 Hz, 1H), 6.26 (d, J=16.8 Hz, 1H), 6.06 (s, 1H), 5.76 (d, J=10.0 Hz, 1H), 4.89 (s, 2H), 3.77 (s, 3H), 3.01 (m, 4H), 2.45 (m, 4H), 2.23 (s, 3H).

LCMS (ESI): m/z 625.2 [M+H]⁺

Example 47N-(3-(3-(3-cyanophenyl)-7-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide (C-EGF36)

[Image Omitted]

This compound was synthesized with similar procedures to that of example 4.

¹H NMR (400 Hz, DMSO-d6) Î´ 10.34 (s, 1H), 8.18 (s, 1H), 7.97 (s, 1H), 7.82 (d, J=6.4 Hz, 2H), 7.71-7.74 (m, 2H), 7.64 (t, J=8.0 Hz, 1H), 7.60 (s, 1H), 7.46 (t, J=8.0 Hz, 1H), 7.30 (d, J=8.8 Hz, 1H), 7.09 (d, J=7.6 Hz, 1H), 6.52 (d, J=2.0 Hz, 1H), 6.47 (dd, J=10.0, 16.8 Hz, 1H), 6.26 (d, J=16.8 Hz, 1H), 6.06 (d, J=6.4 Hz, 1H), 5.76 (d, J=11.2 Hz, 1H), 4.92 (s, 2H), 3.77 (s, 3H), 3.01 (m, 4H), 2.43 (m, 4H), 2.22 (s, 3H).

LCMS (ESI): m/z 616.3 [M+H]⁺

Example 48N-(3-(7-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-3-(3-nitrophenyl)-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide (C-EGF37)

[Image Omitted]

This compound was synthesized with similar procedures to that of example 4.

LCMS (ESI): m/z 636.3 [M+H]⁺

Example 49N-(3-(3-(3-chloro-4-fluorophenyl)-7-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide (C-EGF38)

[Image Omitted]

This compound was synthesized with similar procedures to that of example 4.

LCMS (ESI): m/z 643.2 [M+H]⁺

Example 50N-(3-(7-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-2-oxo-3-o-tolyl-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide (C-EGF39)

[Image Omitted]

This compound was synthesized with similar procedures to that of example 4.

LCMS (ESI): m/z 605.3 [M+H]⁺

Example 51N-(3-(7-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)ethenesulfonamide (C-EGF40)

[Image Omitted]

This compound was synthesized with similar procedures to that of example 4.

LCMS (ESI): m/z 565.2 [M+H]⁺

Example 52N-(3-(3-benzyl-7-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)-4-fluorophenyl)acrylamide (C-EGF41)

[Image Omitted]

This compound was synthesized with similar procedures to that of example 4. LCMS (ESI): m/z 623.3 [M+H]⁺

Example 53In Vitro Enzymatic Activity Assay of 7-(Substituted Amino)-3,4-Dihydropyrimido[4,5-d]pyrimidin-(1H)-Ones Against the Wild Type EGFR and T790M Mutant EGFR

In vitro enzymatic activity assay: using Zâ€²-LYTEâ„¢ technology (detect fluorescence, coupled-enzyme format, based on the differential sensitivity of phosphorylated and non-phosphorylated peptides to proteolytic cleavage), based on FRET, using Zâ€² LYTEâ„¢ FRET peptide substrate, detect the activity of compounds against enzymatic. (invitrogen, Zâ€²-LYTEâ„¢ KINASE ASSAY KIT-TYR 2 PEPTIDE, PV3191) EGFR T790M kinase (invitrogen, PV4803) was diluted progressively, then FRET-peptide, ATP and different concentrations of compound are added to the solution. After one hour, site specific protease which can recognize and cleaves non-phosphorylated FRET-peptide. After another hour, using an excitation wavelength of 400 nM excites, then detect the absorption at 445 nm and 520 nm.

$\dot{\underset{.}{E}} î¢ž mission î¢ž î¢ž Ratio = \frac{Coumarin î¢ž î¢ž Emission î¢ž î¢ž (445 î¢ž î¢ž nm)}{Fluorescein î¢ž î¢ž Emission î¢ž î¢ž (520 î¢ž î¢ž nm)}$ $% î¢ž î¢ž Phosphorylation = 1 - \frac{(Emission î¢ž î¢ž Rate Ã— F î¢ž î¢ž 100 î¢ž %) - C î¢ž î¢ž 100 î¢ž %}{(C î¢ž î¢ž 0 î¢ž % - C î¢ž î¢ž 100 î¢ž %) + [Emission î¢ž î¢ž Ratio Ã— (F î¢ž î¢ž 100 î¢ž % - F î¢ž î¢ž 0 î¢ž %)]}$

The inhibition rate was positively correlated with the drug concentration, then make the kinase activity and concentration curves, the IC₅₀will be calculated.

TABLE 1kinase activity results of the compounds.CompdEGFRWTEGFRT790MEGFRL858REGFRL861QEGFRL858R + T790MC-EGF06â‰¦10 nMâ‰¦10 nMâ‰¦10 nMâ‰¦10 nMâ‰¦10 nMC-EGF0810 nM-100 nM10 nM-100 nM10 nM-100 nM10 nM-100 nM10 nM-100 nMC-EGF0910 nM-100 nM10 nM-100 nM10 nM-100 nMâ‰¦10 nM10 nM-100 nMC-EGF10â‰¦10 nMâ‰¦10 nM10 nM-100 nM10 nM-100 nM10 nM-100 nMC-EGF1110 nM-100 nM100 nM-1000 nM10 nM-100 nMâ‰¦10 nM10 nM-100 nMC-EGF1210 nM-100 nM100 nM-1000 nM10 nM-100 nMâ‰¦10 nM10 nM-100 nMC-EGF13â‰¦10 nMâ‰¦10 nMâ‰¦10 nMâ‰¦10 nMâ‰¦10 nMC-EGF14â‰¦10 nM10 nM-100 nMâ‰¦10 nMâ‰¦10 nM10 nM-100 nMC-EGF1510 nM-100 nM10 nM-100 nMâ‰¦10 nMâ‰¦10 nMâ‰¦10 nMC-EGF16â‰¦10 nM10 nM-100 nMâ‰¦10 nMâ‰¦10 nMâ‰¦10 nMC-EGF17â‰¦10 nMâ‰¦10 nMâ‰¦10 nMâ‰¦10 nMâ‰¦10 nMC-EGF181000 nM-10000 nMâ‰§10000 nMâ€ƒâ€‚â‰§10000 nMâ€ƒâ€‚â‰§10001000 nM-10000 nMC-EGF19â‰§10000 nMâ€ƒâ€‚â‰§10000 nMâ€ƒâ€‚â‰§10000 nMâ€ƒâ€‚100 nM-1000 nM1000 nM-10000 nMC-EGF20â‰¦10 nMâ‰¦10 nMâ‰¦10 nMâ‰¦10 nMâ‰¦10 nMC-EGF21100 nM-1000 nMâ‰§10000 nMâ€ƒâ€‚100 nM-1000 nM1000 nM-10000 nM100 nM-1000 nMC-EGF22â‰¦10 nM10 nM-100 nMâ‰¦10 nMâ‰¦10 nM10 nM-100 nMC-EGF23â‰¦10 nM10 nM-100 nMâ‰¦10 nMâ‰¦10 nM10 nM-100 nMC-EGF24â‰¦10 nMâ‰¦10 nMâ‰¦10 nMâ‰¦10 nMâ‰¦10 nMC-EGF25â‰¦10 nMâ‰¦10 nMâ‰¦10 nMâ‰¦10 nMâ‰¦10 nMC-EGF26â‰¦10 nMâ‰¦10 nMâ‰¦10 nMâ‰¦10 nMâ‰¦10 nMx001â‰¦10 nMâ‰¦10 nMâ‰¦10 nMâ‰¦10 nMâ‰¦10 nMX002â‰¦10 nMâ‰¦10 nMâ‰¦10 nMâ‰¦10 nMâ‰¦10 nMX003â‰¦10 nMâ‰¦10 nMâ‰¦10 nMâ‰¦10 nMâ‰¦10 nMX004â‰¦10 nMâ‰¦10 nMâ‰¦10 nMâ‰¦10 nMâ‰¦10 nMX005â‰¦10 nMâ‰¦10 nMâ‰¦10 nMâ‰¦10 nMâ‰¦10 nMX006â‰¦10 nM10 nM-100 nM10 nM-100 nM10 nM-100 nM10 nM-100 nMX007â‰¦10 nMâ‰¦10 nMâ‰¦10 nMâ‰¦10 nMâ‰¦10 nMX008â‰¦10 nM10 nM-100 nMâ‰¦10 nMâ‰¦10 nMâ‰¦10 nMX009â‰¦10 nM10 nM-100 nMâ‰¦10 nMâ‰¦10 nMâ‰¦10 nMX010â‰¦10 nMâ‰¦10 nMâ‰¦10 nMâ‰¦10 nMâ‰¦10 nMX011â‰¦10 nMâ‰¦10 nMâ‰¦10 nMâ‰¦10 nMâ‰¦10 nMC-EGF27â‰¦10 nMâ‰¦10 nMâ‰¦10 nMâ‰¦10 nMâ‰¦10 nMC-EGF28â‰¦10 nMâ‰¦10 nMâ‰¦10 nMâ‰¦10 nMâ‰¦10 nMC-EGF29â‰¦10 nMâ‰¦10 nMâ‰¦10 nMâ‰¦10 nMâ‰¦10 nMC-EGF30â‰¦10 nMâ‰¦10 nMâ‰¦10 nMâ‰¦10 nMâ‰¦10 nMC-EGF31â‰¦10 nMâ‰¦10 nMâ‰¦10 nMâ‰¦10 nMâ‰¦10 nMC-EGF32â‰¦10 nMâ‰¦10 nMâ‰¦10 nMâ‰¦10 nMâ‰¦10 nMC-EGF33100 nM-1000 nM1000 nM-10000 nM100 nM-1000 nM1000 nM-10000 nM1000 nM-10000 nMC-EGF341000 nM-10000 nM1000 nM-10000 nM1000 nM-10000 nM1000 nM-10000 nM1000 nM-10000 nMC-EGF35â‰¦10 nMâ‰¦10 nMâ‰¦10 nMâ‰¦10 nMâ‰¦10 nMC-EGF36â‰¦10 nMâ‰¦10 nMâ‰¦10 nMâ‰¦10 nMâ‰¦10 nMC-EGF37â‰¦10 nM10 nM-100 nMâ‰¦10 nMâ‰¦10 nM10 nM-100 nMC-EGF38â‰¦10 nMâ‰¦10 nMâ‰¦10 nMâ‰¦10 nMâ‰¦10 nMC-EGF39â‰¦10 nMâ‰¦10 nMâ‰¦10 nMâ‰¦10 nMâ‰¦10 nMC-EGF40â‰¦10 nM10 nM-100 nMâ‰¦10 nMâ‰¦10 nM10 nM-100 nMC-EGF41â‰¦10 nMâ‰¦10 nMâ‰¦10 nMâ‰¦10 nMâ‰¦10 nMTable1

In the enzymatic activity assay of 7-(substituted amino)-3,4-dihydropyrimido[4,5-d]pyrimidin-(1H)-ones against the EGFR kinase, due to the presence of the irreversible Michael addition reaction with the protein cysteine sites, some compounds show a relatively good inhibitive activity to both the two kinases. Referring to FIGS. 1-22, the compounds C-EGF33, C-EGF34 not containing Michael addition reaction sites show a property of an reversible inhibitor that the inhibitive activity at a relatively high test concentration (1 Î¼M) for inhibiting a kinase is poor, such compounds need a higher concentration to achieve an inhibition effect; this directly reflects that it is very important to introduce a functional group having unsaturated binding site like acryloyl into such compounds, such that the compounds can display an activity for inhibiting kinase at a relatively low concentration and get a relatively small IC50 value. The R₁of 7-(substituted amino)-3,4-dihydropyrimido[4,5-d]pyrimidin-(1H)-ones plays a key role in the interaction between compounds and protein, especially when R₁is aryl, it can get the best activity. When R₁is aryl, no matter R₂is a relatively small group of alkyl branched chain or a bigger rigid aryl, the activity can be maintained, that is, various types of group can tolerated in the R₂position.

Example 54Cell Test of EGFR Activity

Detecting the effect of the compounds on cell proliferation by MTT: 1500 cells/well, NCI-H820 (lung cancer cells, EGFR wild type), A431 (Human epidermal carcinoma, EGFR high expression), HCC827 (lung cancer cells, EGFR E746-A750 deletion), H1975 ((lung cancer cells, EGFR L858R&T790M) were cultured in 96-well plates for 24 h, treated with the compounds in DMSO with various concentrations (DMSO final concentration 1%, 3-5 parallel controls), and 72 h later, added MTT (5 mg/ml, 10 ul/well), and then incubated at 37Â° C. for 4 h. Supernatant was removed, and 150 uL DMSO was added. OD570 was detected and the data were treated by the software GraphPad Prism 4 Demo. The obtained results show that, the treatment with the 7-(substituted amino)-3,4-dihydropyrimido[4,5-d]pyrimidin-(1H)-one compounds can significantly reduce the MTT absorption of the above cells, which means that the 7-(substituted amino)-3,4-dihydropyrimido[4,5-d]pyrimidin-(1H)-one compounds can significantly inhibit the proliferation of the above cells, particularly inhibit the proliferation of two types of cells namely H1975(L858R/T790) and HCC827(DEL746-750); the inhibition rate was positively correlated with the drug concentration. 50% inhibitory concentration (IC50) values thereof were calculated according to the inhibition effect of the 7-(substituted amino)-3,4-dihydropyrimido[4,5-d]pyrimidin-(1H)-one compounds on the growth of the cells and listed in Table 2. (The compounds used were compounds prepared in Examples 1-31 respectively, and shown as the sequence numbers of the examples in the Table 2).

TABLE 2NCI-H820Compd NoH1975 (Î¼M)HCC827 (Î¼M)A431 (Î¼M)(Î¼M)C-EGF060.0850.0522.93>100C-EGF080.1590.15921.2>100C-EGF090.3790.21210.7>100C-EGF100.2130.0281.58>100C-EGF112.560.31017.7>100C-EGF121.530.4098.1635.6C-EGF130.5680.198>100>100C-EGF141.220.188>100>100C-EGF150.449â€”â€”â€”C-EGF160.380â€”â€”â€”C-EGF170.7100.06211.1>100C-EGF18>100>100>1004.85C-EGF1912.1>100>10095.7C-EGF200.143â€”â€”â€”C-EGF2122.511.9>100>100C-EGF221.070.49524.9>100C-EGF233.860.61628.2>100C-EGF240.1290.000224.7>100C-EGF250.5010.1981.2354.6C-EGF260.1460.00752.6>100x0010.1150.0293.97>100X0020.4200.1548.03>100X0030.1790.1253.44>100X0040.2610.181>100>100X0050.3330.02316.2>100X0060.5430.10862.5>100X0070.6960.2563.48>100X0081.100.17929.9>100X0090.7100.003>5.0>100X0100.1730.0531.4541.5X0110.0240.0410.360>100C-EGF270.0160.0030.11â€”C-EGF280.0300.0060.57â€”C-EGF290.0140.0030.17â€”C-EGF300.0950.0181.21â€”C-EGF310.0480.0141.20â€”C-EGF320.0330.0231.15â€”C-EGF33>204.89>30â€”C-EGF34>206.79>30â€”

As can be seen from FIGS. 23, 24, 25 and 26, 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives obviously inhibit the growth of H1975 (L858R/T790M) and HCC827 (DEL 746-750) cell lines, while do not significantly suppress the growth of A431 (High level) and NCI-H820 (WT) at low concentration. In the meantime, we also investigated the cytotoxicity of 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives to the normal human cell, HL7702 (WT), where these compounds displayed low toxicity. These results demonstrated that these 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives can be used to target the gefitinib-resistant lung cells with single or multi mutations, but show low toxicity to wild-type lung cells or normal cells. Therefore, the selectivity has significant advantage in clinic.

Example 55Effect of 7-(substituted amino)-3,4-dihydropyrimido[4,5-d]pyrimidin-(1H)-one compounds on H1975 cell apoptosis and cell cycle

Detecting the effect of the compounds on cell apoptosis by Annexin V: 8Ã—10⁵cells/well, NCI-H820, A431, HCC827, EGFR E746-A750 deletion, H1975 were plated in 6-well plates, and 24 h later, treated with the compounds at various concentrations and a control (1% DMSO) for 24, 48 h. Growth medium was collected and cells were trypsined and collected correspondingly to the medium. Suspension (500 g) was centrifuged for 10 minutes. The cells were re-suspended in PBS to get a suspension and then the suspension (500 g) centrifuged for 10 min; this step was repeated twice. The cells were re-suspended in binding buffer, 5Ã—10⁵-1Ã—10⁶cells/mL. PE-Annexin V (556421, BD Pharmingen) 5 mL respectively. The cells were incubated for 15 min at RT in the dark. The samples were detected with FACS Calibur flow cytometer (Becton Dickinson).

Detecting the effect of the compounds on cell cycle by PI: 8Ã—10⁵cells/well, NCI-H820, A431, HCC827, EGFR E746-A750 deletion, H1975 were plated in 6-well plates, and 24 h later, treated with the compounds at various concentrations and a control (1% DMSO) for 24, 48 h. Cells were trypsined, collected and then centrifuged for 10 minutes. The cells were re-suspended in PBS to get a suspension and then the suspension (500 g) centrifuged for 10 min; this step was repeated twice: firstly 300 uL pre-cooled PBS was added and mixed, then 700 uL pre-cooled (i.e. âˆ’20Â° C.) anhydrous ethanol was added and mixed, placed in âˆ’20Â° C. for 24 h. The mixture was 5000 rpm centrifuged for 2 min, washed by PBS twice, resuspended with 200 uL PBS (it needs to ensure the cell concentration as about 10^âˆ’6), added RNase to achieve the final concentration of 50 ug/mL, and trypsined at 37Â° C. for 30 min. The mixture was added PI achieve the final concentration of 10 ug/mL, dyed in dark for 30 min, and then detected within 1 h.

Compound C-EGFRO6 can significantly induce cell cycle arrest and cell apoptosisi. The results can be seen in FIGS. 27, 28 and 29.

Example 56The Effects of 7-(substituted amino)-3,4-dihydropyrimido[4,5-d]pyrimidin-(1H)-one compounds on Cell Signaling Pathway in H1975 Cell

Conventional Western Blot (Immune blotting method) was used, wherein the method includes four steps: sample preparation, electrophoretic separation, film transfer of protein, and immuno hybridization and color display (protein detection). Sample preparation

- 1. culturing cells or treating the cells with drugs;
- 2. discarding mediums, washing the cells with 1Ã—PBS twice to completely remove the mediums;
- 3. adding 1Ã—SDS sample buffer (6-well plate, 100 Î¼l/w or 75 cm²plate, 500-1000 Î¼l/bottle), scrapping the cells and transferring them to Ep tube;
- 4. ultrasonic shearing DNA for 10-15 seconds to reduce the viscosity of the sample;
- 5. boiling the sample for 5 minutes;
- 6. centrifuging 12000 g sample for 5 minutes and taking the supernatant.
  Electrophoretic separation: Taking 15-20 Î¼L supernatant to SDS-PAGE gel (10 cmÃ—10 cm) to electrophoretic separate.
- Electrophoretic Separation (Pleaes Refer to SDS-PAGE Electrophoretic Separation Method) Film Transfer
- 1. immersing the gel in a transferring buffer to balance for 10 min;
- 2. clipping 6 sheets of film and filter paper according to the size of the gel, putting the sheets into the transferring buffer to balance for 10 min, wherein PVDF film should be immersed in pure methanol for 3-5 seconds;
- 3. installing a transfer sandwich: spongeâ†’3 layers of filter paperâ†’gelâ†’filmâ†’3 layers of filter paperâ†’sponge, driving away bubbles when each layer is placed;
- 4. putting a transfer tank in ice bath, placing the sandwich in (with black surface facing black surface), adding the transfer buffer, plugging electrodes with 100 V, 1 h (the current is 0.3 A); when the film transfer is completed, shutting off the power supply and taking out the hybrid film.

Immuno Hybridization and Color Display

- 1. washing the film with 25 mL TBS for 5 min at RT, shaking;
- 2. placing the film in 25 mL sealed buffer for 1 h at RT, shaking;
- 3. washing the film with 15 mL TBS/T for six times (5 min/T);
- 4. adding a primary antibody with appropriate dilution, incubating at RT for 1-2 h or overnight at 4Â° C.;
- 5. washing the film with 15 mL TBS/T for six times (5 min/T);
- 6. adding a secondary antibody with appropriate dilution, labeled by AP or HRP, incubating at RT for 1 h, shaking slowly;
- 7. washing the film with 15 mL TBS/T for three times (5 min/T);
- 8. washing the film with 15 mL TBS for one time;
- 9. preparing protein tablet by ECL;
- 10. developing.

Compound C-EGF06 can significantly induce EGFR phosphorylation arrest, and further block the downstream pathway phosphorylation, as illustrated in FIG. 30.

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents of the specific embodiments of the invention described herein. Such equivalents are intended with be encompassed by the following claims.